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ABSTRACT OF DISSERTATION

NEURAL MECHANISMS OF SYMPATHETIC ACTIVATION DURING
HYPERINSULINEMIA AND OBESITY-INDUCED HYPERTENSION

Obesity afflicts more than 30% of the U.S. population and is a major risk factor
for the development of hypertension, type II diabetes, and cardiovascular
disease. Studies in humans and animals indicate that obesity is associated with
increased sympathetic outflow to the vasculature and kidneys. One mechanism
postulated to underlie the increase in sympathetic nerve activity (SNA) in obesity
is hyperinsulinemia. Little is known regarding the central circuitry underlying
elevated SNA and arterial blood pressure (ABP) during hyperinsulinemia and
obesity or if sympathoexcitatory circuits are still responsive to insulin in obesity.
Hyperinsulinemic-euglycemic clamps elevate SNA to the hind limb vasculature in
lean rodents but obesity is associated with resistance to the peripheral and
anorexic effects of insulin. Therefore, the first aim was to determine whether
diet-induced obesity causes development of insulin resistance in the central
circuits mediating SNA. The sympathoexcitatory response to insulin was still
intact in diet-induced obese rats indicating a role for insulin in the elevation in
SNA and ABP in obesity.
The second aim of this project was to identify the specific receptors in the rostral
ventrolateral medulla (RVLM) that mediate the elevated SNA during
hyperinsulinemia. The RVLM provides basal sympathetic tone and maintains
baseline ABP. Glutamate is the major excitatory neurotransmitter and glutamate
receptors of the RVLM are known to mediate multiple forms of hypertension.
Blockade of RVLM NMDA-specific glutamatergic receptors reverses the
increased lumbar SNA associated with hyperinsulinemia. In contrast, blockade
of angiotensin II type 1 or melanocortin receptors in the RVLM had no effect on
the sympathoexcitatory response to insulin.
The goal of the third aim was to identify the cellular mechanisms within RVLM
that mediate the elevated SNA and ABP in diet-induced obesity. Blockade of
RVLM glutamate receptors reversed the elevated ABP and lumbar SNA

associated with diet-induced obesity while it had no effect on rats on a low fat
diet or those resistant to weight gain on the high fat diet. Similar to the findings
during hyperinsulinemia, blockade of RVLM angiotensin II type 1 or melanocortin
receptors had no effect on lumbar SNA or ABP during diet-induced obesity.

KEYWORDS: Obesity, Hyperinsulinemia, Rostral Ventrolateral Medulla,
Sympathetics, Blood Pressure
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Chapter I: Introduction
Obesity
1.1 Prevalence of Obesity
Obesity is a growing pandemic in industrialized as well as developing
countries (Garrison et al. 1987).

More than 30% of adults in the United States

have a body mass index (BMI) greater than 30 while nearly 70% have a BMI
greater than 25, therefore classified as overweight (Garrison et al. 1987).
Obesity is associated with increased adiposity, insulin resistance,
hyperinsulinemia, hyperleptinemia, and elevated cholesterol levels. Obesity is
linked with decreased life expectancy of 5-20 years (Fontaine et al. 2003) and
increased morbidity due to its causative association with hypertension, type II
diabetes, atherosclerosis and cardiovascular diseases (Izzo et al. 2008, van
Dieren et al. 2010). In addition, obesity is thought to exacerbate a number of
health problems including metabolic and hormonal conditions, reproductive
dysfunction, and cancer (Reeves et al. 2007). The development of obesity is
determined both by genetics and lifestyle choices. Body weight is maintained by
an extensive negative feedback system (Woods et al. 2004) based on stored fat,
caloric intake, and energy expenditure. The majority of obesity is the result of
decreased physical activity and increased caloric intake. As our society
becomes more sedentary, daily energy expenditure decreases while energy
intake remains unchanged or even increases due to the easy access to fast food
and pre-packaged, high calorie foods. The uneven balance of excess dietary
caloric intake over energy expenditure leads to glucose storage, fat mass
deposition, and an increase in body weight.
1.2 Obesity-Induced Hypertension
One of the major health concerns associated with obesity is elevated
arterial blood pressure (ABP) or hypertension (Izzo et al. 2008). There is a
positive correlation between hypertension and adiposity and relative weight when
adjusted for age in both males and females (Garrison et al. 1987). Individuals,
1

age 20-49, were studied over an 8 year time frame. The most common
potentially modifiable characteristic predetermining individuals for hypertension
was elevated body fat (Garrison et al. 1987). From this relationship, it can be
garnered that as body weight increases with obesity, ABP will also rise which
occurs in humans, dogs and rodents (Dobrain et al. 2000, Kassab et al. 1995).
This is clinically relevant because only a ~5 mmHg increase in ABP significantly
increases the risk for stroke and myocardial infarction (Izzo et al. 2008, Strazzulo
et al. 2010). Convincing evidence indicates that elevated sympathetic nerve
activity (SNA) leads to the pathogenesis of obesity-induced hypertension in
humans, dogs, and rodents (Esler et al. 2006, Wofford and Hall 2004).
Landsberg has hypothesized that obesity results in activation of the sympathetic
nervous system as a compensatory mechanism. The increase in SNA helps to
stabilize energy expenditure and restore body weight following overfeeding by
elevating thermogenesis. But the result is an overall increase in SNA to the
kidneys and vasculature raising blood pressure as a “side effect” (Landsberg
1986).
1.3 Sympathetic Nerve Activity
The sympathetic nervous system is the portion of the autonomic nervous
system known as “fight or flight”. Sympathetic neurons project to many organ
systems where norepinephrine is released from nerve terminals. Activation of
the sympathetic nervous system causes multiple physiological changes
including: increased heart rate, increased blood flow to skeletal muscle, and
dilated pupils. There are multiple techniques used to measure SNA in human
subjects: ganglionic blockade, plasma and urinary norepinephrine levels, regional
norepinephrine spillover, and microneurography. In obese humans, ganglionic
blockade causes a significantly greater reduction in ABP and total peripheral
resistance compared to lean subjects indicative of sympathetic activation (Shibao
et al. 2007). When plasma norepinephrine is measured in obese humans, there
are confounding reports (Grassi et al. 1995, Vaz et al. 1997). This could be
because plasma measurements are insensitive, that norepinephrine released
2

from sympathetic fibers is taken back up or destroyed before entering the
circulation, or that all nerve beds do not respond equally to a given stimuli (Esler
et al. 1990). A more precise measure is regional norepinephrine spillover. When
measured in obese vs lean subjects, obesity leads to increased renal SNA,
decreased cardiac SNA, and unchanged hepatomesenteric SNA (Grassi et al.
1995, Vaz et al. 1997). These particular studies demonstrate the possibility for
region specific changes in SNA associated with obesity. Measures of muscle
SNA via microneurography have provided the most convincing evidence for
elevated SNA associated with obesity. The first study, in 1995, demonstrated
that muscle SNA is elevated in obese normotensive subjects compared to lean
controls (Grassi et al. 1995). This highlighted the fact that development of
obesity-induced hypertension is preceded by elevation in SNA. This might
explain why weight loss decreases blood pressure even in non-hypertensive
obese subjects (Neter et al. 2003). With that, a comparison of muscle SNA
between obese-normotensive and obese-hypertensive subjects indicates an
even greater elevation in muscle SNA (Lambert et al. 2007). Interestingly, even
a modest weight gain, below what is classically considered obese, causes a
significant increase in muscle SNA that is associated with a small, but significant
elevation in systolic blood pressure (Gentile et al. 2007).
Similar results have been found in both dogs and rodents. Putting dogs or
rodents on a high fat diet produces obesity-induced hypertension (Lohmeier et al.
2007, Stocker et al. 2007). Obese dogs have elevated plasma norepinephrine
levels while obese rodents show elevated urinary catecholamines (Levin 1993,
Lohmeier et al. 2007). Similar to humans, treatment with ganglionic blockers
decreases blood pressure to the same level as lean animals (Truett et al. 1996,
D‟Angelo et al. 2006). As well, renal denervations prior to high fat feeding in
dogs prevent the development of obesity-induced hypertension suggesting an
important role for renal SNA (Kassab et al. 1995). In conjunction, obese Zucker
rats, which have a mutation of the leptin receptor encoding gene, are
hypertensive and it appears to be modestly dependent on increased SNA
(Morgan et al. 1995, Carlson et al. 2000). This connection between obesity and
3

activation of the sympathetic nervous system provides a possible point for
medical intervention but what is causing the elevation in SNA must be
determined.
There are multiple factors proposed to play a role in elevating SNA and
ABP in obesity. These include but are not limited to arterial baroreceptor reflex
dysfunction, activation of the renin-angiotensin system, elevated circulating
insulin and leptin levels, and obstructive sleep apnea (da Silva et al. 2009, Esler
et al. 2006). Obesity is associated with impaired baroreflex function (Grassi et al.
2004) and although the baroreflex is traditionally thought to control ABP on a
minute to minute basis, recently studies indicate a role for the baroreflex in longterm hypertension (Guyenet 2006). Chronic stimulation of the baroreflex in
obese dogs causes a 20 mmHg fall in ABP associated with a parallel decrease in
plasma norepinephrine with no change in either variable in lean controls
(Lohmeier et al. 2007).
Angiotensin II is an important regulator of ABP and renin-angiotensin
system activation appears to correlate with obesity-induced hypertension (Hall
2003, Boustany et al. 2004). In humans, angiotensin II, angiotensinogen, plasma
renin activity, and angiotensin converting enzyme activity are all positively
associated with BMI. And though there is a correlation between RAS activity and
blood pressure, its effects on SNA are confounding. Ganglionic blockade lowers
ABP to a similar level in rats that received chronic intracerebroventricular
administration of angiotensin II (Bruner and Fink et al. 1986). As well,
angiotensin II receptor blockade decreases muscle SNA in hypertensive humans
(Grassi et al. 2003, Bechir et al. 2005). Celiac ganglionectomy, which removes
neurotransmission to the splanchnic vasculature, markedly attenuates the
hypertension associated with angiotensin II-salt (King et al. 2007). In contrast,
chronic angiotensin II infusion in dogs does not increase renal SNA (Carroll et al.
1984) nor does it increase renal or lumbar SNA in rats on a low or high salt diet
(Yoshimoto et al. 2010).
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Obstructive sleep apnea is common in obesity and can result in significant
activation in SNA through the night (Narkiewicz et al. 1998). It is proposed that
over time this night time activation evolves into a round-the-clock increase in
SNA. Obstructive sleep apnea has even been shown to raise SNA in lean
individuals (Grass et al. 2005). But there is no mechanism through which a
transfer of night time activation to full time activation works and treatment of
obstructive sleep apnea does not decrease SNA (Mills et al. 2006).
Insulin and leptin levels both correlate positively with obesity-induced
hypertension. Insulin and leptin circulate in proportion to body fat stores and gain
access into the central nervous system through a transport-mediated mechanism
across the blood brain barrier. Acutely, both insulin and leptin activate the
sympathetic nervous system while chronic infusion in rodents increases ABP
(Brands et al. 1991, Morgan DA et al. 1993, Rahmouni et al. 2009, Tallam et al.
2006). Taken together, multiple characteristics of obesity could lead to an
increase in SNA and elevation of ABP and this dissertation focuses specifically
on the role of insulin.
Insulin
2.1 Insulin Signaling
Two hallmark characteristics of obesity are hyperinsulinemia and insulin
resistance. The peptide hormone insulin circulates in proportion to body fat
stores (Woods et al. 1985) and is synthesized as a preprohormone in pancreatic
β-cells. Preproinsulin is cleaved in the endoplasmic reticulum (ER) to generate
proinsulin which is transported to the Golgi apparatus where it is acted on by
proteolytic enzymes to generate the physiologically active form of insulin. Insulin,
a 6000 Da protein, consists of 2 polypeptide chains connected by disulfide bonds
(Derewenda et al. 1986). Insulin is stored as a stable, inactive hexamer, thus
protecting the highly reactive monomer form. Insulin is released from pancreatic
β-cells in response to elevated blood glucose levels (i.e. following a meal).
Glucose enters pancreatic β-cells through the GLUT-2 transporter where it
5

undergoes glycolysis. The resultant shift in ATP/ADP ratio triggers ATP-sensitive
K+ channels to close. Upon depolarization, voltage gated Ca 2+ channels open
and the increased Ca2+ activates phospholipase C which cleaves the membrane
phospholipid phosphatidyl-inositol 4, 5-bisphosphate (PIP2) into inositol 1, 4, 5triphosphate (IP3). IP3 binds to its receptor protein on the ER membrane allowing
the release of Ca2+ from the ER. The increased intracellular Ca 2+ concentration
triggers the release of insulin stored in secretory vesicles.
Insulin is the major hormone controlling glucose homeostasis in peripheral
tissues. Insulin stimulation leads to translocation of GLUT-4 transporters from an
intracellular location to the cell surface (Thorell et al. 1999). It stimulates glucose
uptake into skeletal muscle, glycogen synthesis in the liver and fat deposition in
adipocytes (Barnard and Youngren 1992). The insulin receptor is a protein
tyrosine kinase found throughout the body. When insulin binds to the
extracelluar α-subunit it autophosphorylates the β-subunit giving the receptor the
ability to phosphorylate other residues including insulin receptor substrates (IRS
1 and IRS 2). Tyrosine phosphorylated IRS 1 and IRS2 bind src homology 2
domain containing signaling proteins and can associate with phosphatidylinositol
3-kinase (PI3K, mediates the metabolic actions of insulin) or mitogen-activated
protein kinase (MAPK, mediates the proliferative effects of insulin) ( Sale et al.
1995, Jhun et al. 1995). PI3K and MAPK are able to activate many downstream
signaling pathways including JNK, Akt/PKB, mTOR, etc (Figure 1). Insulin
administration significantly increases PI3K activation in skeletal muscle while
specific inhibition of PI3K eliminates insulin-stimulated glucose uptake (Cheatham
et al. 1994, Le Marchand-Brustel et al. 1995). As well as insulin‟s effects on
glucose uptake; insulin stimulates DNA replication and protein synthesis,
increases glycogen synthesis in the liver, increases fatty acid synthesis,
decreases gluconeogenesis, and modifies the activity of numerous enzymes.
2.2 Central Insulin Signaling
Insulin‟s actions in the brain vary greatly from that seen in peripheral
tissues in that insulin is not necessary for neuronal glucose uptake, and in fact
6

does not influence brain glucose concentrations (Seaquist et al. 2001). Under
normal conditions, insulin has three main actions in the central nervous system:
1) decrease food intake, 2) increase energy expenditure, and 3) activate the
sympathetic nervous system. Most of what we know about insulin‟s central
actions comes from the food intake field. Insulin was the first hormone implicated
in control of food intake and body weight and is able to cross the blood brain
barrier in a transport specific mechanism (Banks et al. 1997, Woods and Porte
1977) in direct proportion to circulating insulin levels. Insulin receptors are
expressed throughout the central nervous system and are concentrated in brain
regions known to control food intake such as the hypothalamus (Hill et al. 1986,
Werther et al. 1987). Intracerebroventricular administration of insulin results in a
profound decrease in food intake and body weight (Woods et al. 1979,
Niswender et al. 2003). In contrast, injection of insulin receptor antisense into
the hypothalamus significantly decreases insulin receptor expression which
results in extreme hyperphagia and weight gain (Obici et al. 2002).
The signaling pathways involved centrally appear to be similar to those
utilized in the periphery. Niswender (2003) demonstrated that insulin stimulates
tyrosine phosphorylation of the insulin receptor, increases IRS-2 activity in the
hypothalamic arcuate nucleus (ARC), and increases PI3K activity in the
mediobasal hypothalamus. As well, studies have shown that insulin‟s anorexic
effects are dependent on activation of PI3K as blockade abolishes the normal
decrease in food intake (Carvalheira et al. 2003, Niswender et al. 2003).
The neuronal populations through which insulin acts to decrease food
intake have been extensively studied. Insulin acts in the brain to activate a
catabolic pathway while simultaneously inhibiting a separate anabolic pathway.
These two pathways involve insulin acting on pro-opiomelanocortin (POMC) and
neuropeptide-Y (NPY)/agouti related protein (AgRP) neurons, respectively
(Morton et al. 2001, Schwartz et al. 2000). Insulin receptors are co-expressed
with both POMC and NPY in the arcuate nucleus (Obici et al. 2001, Pardini et al.
2006) and central administration of insulin significantly increases POMC and
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decreases NPY/AgRP expression. Activation of POMC neurons results in an
increased release of α-melanocyte stimulating hormone (α-MSH) which binds to
and activates melanocortin receptors which leads to a decrease in food intake.
At the same time, inhibition of NPY/AgRP neurons decreases both NPY and
AgRP release and because AgRP is a melanocortin receptor antagonist this also
decreases food intake (Figure 2) (Schwartz 2000). The discovery that the
hypothalamic melanocortin system is the major regulator of food intake is
supported by the finding that central blockade of melanocortin receptors inhibits
insulin‟s effects on food intake (Benoit et al. 2002) and the hyperphagia
associated with type II diabetes results in an increase in NPY synthesis and
release which is reversed by central insulin administration.
2.3 Insulin and Sympathetic Nerve Activity
Hyperinsulinemia activates the sympathetic nervous system (Anderson et
al. 1991), is associated with obesity-induced hypertension (Modan et al. 1984),
and is therefore postulated to play a role in activation of SNA in obesity-induced
hypertension (Esler et al. 2006). Previous studies show a correlation between
elevated plasma insulin levels and activation of the sympathetic nervous system
in obese subjects (Scherrer et al. 1994, Huggett et al. 2004). Acute
hyperinsulinemic-euglycemic clamps selectively elevate muscle and lumbar SNA
in humans and rodents, respectively (Anderson et al. 1992, Morgan et al. 1993,
Muntzel et al. 1994). This activation of SNA is known to be mediated by central
circuits as intracerebroventricular administration of insulin elevates lumbar SNA
to the same extent and anteroventral third ventricle lesions abolish the
sympathoexcitation (Muntzel et al. 1994). Blockade of central PI3K, but not
MAPK, blunts the increase in lumbar SNA associated with hyperinsulinemia
(Rahmouni et al. 2004). In addition, chronic hyperinsulinemia elevates ABP in
rodents which were associated with an increase in total peripheral resistance
(Brands et al. 1991).
2.4 Altered Insulin Signaling in Obesity

8

Plasma insulin levels are significantly elevated in obese humans and
rodents (Carvalheira et al. 2003). Obesity results in an initial resistance to insulin
which is compensated for by increased output of insulin from the pancreas in
order to maintain euglycemia. Over time, pancreatic β cells can no longer
compensate for the resistance which leads to a significant decrease in insulinstimulated skeletal muscle glucose uptake measured by glucose tolerance tests
(Storlien et al. 1986). This decrease in glucose uptake is not due to a change in
the expression of GLUT-4 receptors but rather is most likely due to impairment in
insulin signaling (Choi and Kim 2010). In obese humans, insulin loses its ability
to stimulate skeletal muscle blood flow which could play a role in the decreased
glucose uptake (Laakso et al. 1990). In fact; it has been shown that PI 3K activity
is decreased in skeletal muscle of type II diabetic (Kim et al. 1999) or obese nondiabetic patients (Cusi et al. 2000). Obesity also results in central insulin
resistance. Intracerebroventricular administration of insulin has a decreased
anorexic effect in both diet-induced obese and Zucker obese rats (Carvalheira et
al. 2003, Clegg et al. 2005, Posey et al. 2009). There is no change in
hypothalamic insulin receptor expression but rather this is associated with
decreased autophosphorylation of the insulin receptor, decreased
phosphorylation of IRS-1 and -2 in the hypothalamus, and significantly
attenuated PI3K signal transduction (Carcalheira et al. 2003, De Souza et al.
2005, Posey et al. 2009). Very little is known in regards to insulin‟s ability to
elevate SNA during obesity. A very recent study demonstrated that agouti obese
mice, in which the agouti protein is over-expressed, which blocks melanocortin
receptors increasing food intake, are selectively resistant to the central effects of
insulin. Intracerebroventricular insulin is still able to increase lumbar SNA but not
renal or brown adipose tissue SNA (Morgan and Rahmouni 2010).
Neural Circuitry
3.1 Rostral Ventrolateral Medulla
The rostral ventrolateral medulla (RVLM) provides basal sympathetic tone
through a direct projection to preganglionic sympathetic fibers of the
9

intermediolateral cell column in the lumbar and thoracic spinal cord (Guyenet
2006). Electrical or chemical stimulation of the RVLM causes a significant
pressor response and increase in SNA (Ross et al. 1984, Bennaroch et al. 1986)
while electrolytic lesions or inhibition of the RVLM result in falls in SNA and ABP
similar to that seen following spinal cord transection or ganglionic blockade (Ross
et al 1984). Although other brain regions innervate sympathetic fibers and when
stimulated increase ABP, the RVLM is regarded as the major vasomotor center.
In vivo electrophysiological studies have identified bulbospinal RVLM
neurons that are tonically active, barosensitive, synchronized with the blood
pressure pulse, and project to the spinal cord (Brown and Guyenet 1984). The
tonic activity of these cells is based on either excitatory synaptic input or intrinsic
pacemaker activity. To be classified as pacemaker cells, neurons must
depolarize without outside input and have a highly regular discharge rate not
preceded by excitatory or inhibitory post-synaptic potentials. Initial studies
indicated that these cells could generate spontaneous action potentials based on
their gradual depolarization (Sun et al. 1988) and ability to continually fire after
application of kynurenic acid, a glutamate receptor antagonist, and hence
blockade of many excitatory inputs to the RVLM (Sun et al. 1988). However,
recordings of dissociated RVLM neurons revealed no such pace-maker
properties (Lipski et al. 1998). Action potentials of RVLM neurons were
preceded by excitatory post-synaptic potentials with no indication of gradual
depolarization (Lipski et al. 1996) which signifies that tonic activity is determined
by synaptic inputs under normal conditions.
Where these synaptic inputs originate and the neurotransmitters involved
to maintain baseline RVLM neuronal activity are not well understood. In cats and
rabbits blockade of glutamatergic input to the RVLM results in a significant
decrease in ABP (Abrahams et al. 1994, Horiuchi and Dampney 2002), where as
it causes no change in rats (Ito and Sved 1997), but this is believed to result due
to blockade of both excitatory and inhibitory neurotransmission. There are direct
monosynaptic projections to the RVLM from the caudal ventrolateral medulla
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(Afarwal and Calaresu 1991), hypothalamic paraventricular nucleus (Shafton et
al. 1998), nucleus of the solitary tract (Ross et al. 1985), area postrema (Shapiro
and Miselis 1985), pontine reticular formation (Krassioukov and Weaver 1993)
and others. Inhibition of the pontine reticular formation results in decreases in
ABP and SNA similar to that seen following RVLM inhibition, but they are short
lasting (Hayes and Weaver 1992). However, inhibition of any of the other
regions does not lead to as significant a decrease in ABP as inhibition of the
RVLM and it is most likely that a combination of regions contribute to the resting
activity of RVLM neurons.
The RVLM is implicated in a number of sympathoexcitatory reflexes such
as the baroreflex (Guyenet 2006), somatic pressor reflex (Stornetta et al. 1989),
chemoreflex (Koshiya et al. 1993), as well as hypothalamic stimulation (Coote et
al. 1998), all of which are affected by destruction or blockade of RVLM
neurotransmission (Granata et al. 1985, Stornetta et al. 1989, Koshiya et al.
1993, Sun and Guyenet 1986). And although the RVLM is made up of a
heterogeneous population of neurons, it is believed that it is the spontaneously
active, spinally projecting neurons specifically which are responsible for
maintaining baseline SNA and ABP and are the major relay station for the
baroreflex involved in minute to minute as well as long term control of ABP.
These neurons play a critical role in cardiovascular regulation and vasomotor
tone.
3.2 Glutamate
RVLM neurons express a number of receptor types and their excitability is
determined by a number of neurotransmitters. L-glutamate, the major excitatory
neurotransmitter elicits profound increases in SNA and ABP when microinjected
in to the RVLM. A glutamatergic connection exists between the hypothalamus
and RVLM (Sun MK and Guyenet 1986). Specifically, glutamate-dependent
connections have been discovered from the paraventricular nucleus (Yang et al.
2001, Stocker et al. 2006) and pontine reticular formation (Krassioukov and
Weaver 1993) to the RVLM. Further evidence exists for a significant role of
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RVLM glutamatergic receptors in that blockade of glutamate receptors in the
RVLM eliminates multiple sympathoexcitatory reflexes including the somatic
pressor reflex (Stornetta et al. 1989) and has been reported to significantly lower
ABP in several experimental models of hypertension (Bergamaschi et al. 1995,
Ito et al. 2000, Ito et al. 2001).
3.3 Renin-Angiotensin System
Though many sympathoexcitatory reflexes are mediated by RVLM
glutamatergic receptors, not all appear to be glutamate-dependent (Kiely and
Gordon 1994). The RVLM expresses an abundance of angiotensin II type
1(AT1) receptors (Song et al. 1991) that when activated increase SNA and ABP
(Dampney et al. 2002). The increases in ABP and renal SNA associated with
activation of the paraventricular nucleus by disinhibition appear to be mediated
by RVLM AT1 receptors (Tagawa and Dampney 1999). Similar to RVLM
glutamate receptors, blockade of AT1 receptors abolishes hypertension in a
number of experimental models including both spontaneously and salt-sensitive
hypertensive rats (Ito et al. 2002, Ito et al. 2003).
Inhibition of angiotensin converting enzyme or blockade of AT1 receptors
in the brain blunts the sympathoexcitatory response to hyperinsulinemia (Muntzel
et al. 1994, Nakata et al. 1998). In addition, blockade of the renin-angiotensin
system prevents insulin-induced hypertension (Brands et al. 1997) and dietinduced obesity hypertension in rodents (Boustany et al. 2005). Importantly,
angiotensin-converting enzyme inhibition has been reported to be an effective
therapy in obese, hypertensive subjects (Reisin et al. 1997) while angiotensin II
receptor blockade lowers SNA in obese-hypertensive subjects (Grassi et al.
2003, Bechir et al. 2005).
3.4 Melanocortin System
The central melanocortin system has been extensively implicated in the
control of food intake (Schwartz et al. 2000) and is hypothesized to be equally as
important in control of SNA. Melanocortin 3/4 receptors are expressed
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throughout the brain, including the RVLM (Adan and Gispen 1997, Adan and
Gispen 2000) where activation increases SNA and ABP (Kawabe et al. 2006).
Interestingly, approximately 3-6% of extreme obese cases in humans are due to
a mutation in the melanocortin-4 receptor. The prevalence of hypertension is
significantly decreased in these subjects as is urinary norepinephrine secretion
(Greenfield et al. 2009) and muscle SNA (Sayk et al. 2010). Similarly, the
sympathoexcitatory response to insulin is abolished in melanocortin-4 receptor
knockout mice (Rahmouni et al. 2003). While these mice are extremely obese,
they do not become hypertensive despite elevated plasma insulin concentrations
(Tallam et al. 2005). In addition, intracerebroventricular infusion of the
melanocortin receptor antagonist SHU 9119 significantly lowers ABP in dietinduced obese rats (Dubinion et al. 2010), significantly decreases renal SNA in
obese mice (Morgan et al. 2008), significantly lowers ABP in spontaneously
hypertensive rats (da Silva et al. 2008), and prevents the anorexic actions of
insulin (Benoit et al. 2002).
Summary and Specific Aims
Obesity affects a large percentage of the United States population and is a
major determinate in the development of essential hypertension. Multiple studies
in humans and rodents indicate that obesity-induced hypertension is due to
increased SNA to the hindlimb vasculature. One possible signal elevating SNA
in obesity is hyperinsulinemia. Obese humans and rodents have elevated
plasma insulin levels and acute hyperinsulinemic-euglycemic clamps elevate
muscle and lumbar SNA, respectively. As well, chronic hyperinsulinemiceuglycemic clamps elevate arterial blood pressure in rodents. These actions are
mediated by the central nervous system as acute ICV administration of insulin
elevates lumbar SNA. Altogether these findings indicate that obesity causes
hyperinsulinemia and the increased insulin acts centrally through an unidentified
pathway to increase SNA and ABP. But it is still unknown whether insulin is able
to stimulate the sympathetic nervous system in obesity or if these circuits
become insulin resistant. As well, the brain regions mediating the increase in
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SNA and ABP during hyperinsulinemia and obesity remain to be discovered.
Therefore, this dissertation aimed to examine the central mechanisms through
which insulin and obesity activate the sympathetic nervous system and elevate
arterial blood pressure. Specifically these studies examined:
1. Whether diet-induced obesity results in central resistance to the
sympathoexcitatory effects of insulin
2. Whether glutamate, angiotensin II type 1, or melanocortin receptors of
the RVLM mediate the sympathoexcitatory response to insulin.
3. Whether glutamate, angiotensin II type 1, or melanocortin receptors of
the RVLM are involved in the development of diet-induced obesity
hypertension.
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Figure 1. Insulin signaling pathways (Adapted from Kido et al. 2001)
Insulin signaling includes a vast array of downstream pathways. Activation of the
insulin receptor causes autophosphorylation of the β-subunit followed by tyrosine
phosphorylation of IRS. Downstream signaling cascades include: AKT which is
responsible for activation of mTOR, protein synthesis, and GLUT-4 translocation
and MAPK mediates gene transcription and cell proliferation
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Figure 2. Insulin acts within the hypothalamus to activate a relay station
which results in a decrease in food intake (Adapted from Schwartz et al.
2000).

Copyright © Megan E. Bardgett 2010
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Chapter II: Diet-Induced Obesity Does Not Result in Insulin Resistance in
Sympathetic Circuits
This work has previously been submitted to Brain Research
Specific aim 2 will examine whether diet-induced obesity causes central
resistance to the sympathoexcitatory effects of insulin.

Introduction
The peptide hormone insulin is released from the pancreas and circulates
in direct proportion to the amount of fat stores (Woods et al. 1985). Insulin plays
a pivotal role in the regulation of glucose metabolism, food intake, and body
weight (Schwartz et al. 2000). Insulin stimulates glucose uptake largely in
skeletal muscle, liver, and adipocytes by eliciting translocation of GLUT-4
receptors to the membrane (Barnard and Youngren 1992, Thorell et al. 1999). In
addition, circulating insulin is transported into the brain where it acts in the
hypothalamus to decrease food intake and body weight (Schwartz et al. 2000,
Woods and D‟Alessio 2008).
Obesity and the metabolic syndrome are characterized by a marked
peripheral insulin resistance defined clinically as an inability of insulin to maintain
glucose homeostasis (Storlien et al. 1986, Haas and Biddinger 2009). Obesity is
also associated with a reduction in the central anorexic actions of insulin (Clegg
et al. 2005). In regard to the latter, high-fat feeding significantly attenuates the
insulin-mediated reductions in food intake and body weight of Sprague-Dawley
(Clegg et al. 2005), Osborne-Mendel (Arase et al. 1988), and out-bred and
selectively-bred obesity-resistant (OR) and obesity-prone (OP) rats (Clegg et al.
2005). In fact, the ability of insulin to decrease food intake in out-bred OR and
OP was inversely related to subsequent body weight gain. That is, the blunted
anorexic effect of insulin was associated with, or predicted weight gain on a high
energy diet (Clegg et al. 2005).
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In addition to its anorexic effects, insulin works centrally to activate the
sympathetic nervous system and alter cardiovascular function (Bardgett et al.
2010). Previous studies have clearly demonstrated that a hyperinsulinemiceuglycemic clamp significantly increases lumbar and/or muscle sympathetic
nerve activity (SNA) in rodents and humans, respectively (Anderson et al. 1992,
Morgan et al. 1993, Muntzel et al. 1994). These sympathoexcitatory actions of
insulin are centrally-mediated as intracerebroventricular injection of insulin
produces similar responses (Muntzel et al. 1994, Pricher et al. 2008) and
interruption of central insulin signaling pathways (Rahmouni et al. 2004) or
neurotransmission in the rostral ventrolateral medulla (Bardgett et al. 2010)
prevents the increase in lumbar SNA. Furthermore, hyperinsulinemia is one
mechanism postulated to play a role in the elevated SNA during obesity-induced
hypertension (Esler et al. 2006). If hyperinsulinemia chronically elevated SNA in
obesity, the central circuits that mediate the sympathoexcitatory response could
not be insulin-resistant. Currently, there is not data that directly test this
hypothesis.
Therefore, the purpose of the present study was to determine whether the
central sympathetic circuits were insulin-resistant in diet-induced obesity.
Previous studies have demonstrated that feeding rats a moderate high-fat diet
results in the segregation of obesity-resistant (OR) and obesity-prone (OP) rats
based on body weight gain (Stocker et al. 2007). The latter group has an
elevated arterial blood pressure (ABP), activation of the renin-angiotensin
system, hyperleptinemia, hyperinsulinemia, and elevated sympathetic outflow
(Boustany et al. 2004, Levin et al. 1983, Dobrain et al. 2000, Levin and Keesey
1998). The segregation of OR and OP rats also permits studies to distinguish
between the effects of obesity versus diet composition.
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Materials and Methods
Animals
All of the experimental procedures were approved by the University of
Kentucky and Penn State University Institutional Animal Care and Use
Committee and were conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. Male SpragueDawley rats (Charles River Laboratory) weighing 150 to 200 g were housed in a
temperature-controlled room (22o-23o C) with a 14-hour/10-hour light-dark cycle
(light on at 7:00 AM). Rats were placed on a LF diet (10% kcal from fat;
Research Diets, Inc. D12489B) or a moderate high-fat diet (32% kcal from fat,
Research Diets, Inc. D12266B) for 13 weeks. After 5 weeks, rats fed the
moderately high-fat diet segregate into OP and OR based on body weight
distribution as described previously (Stocker et al. 2007). Briefly, a body weight
histogram was constructed and resulted in a distribution of rats into OP and OR
groups corresponding with the upper and lower one third of rats, respectively.
Rats were anesthetized with isoflurane (2%-3%, 100% O2) and prepared
for recordings of lumbar SNA and ABP as described previously (Scislo et al.
1998, Stocker et al. 2005). Animals were artificially ventilated with oxygenenriched room air. End-tidal CO2 and body temperature were maintained at 4%
to 5% and 37±1o C, respectively. After surgery, anesthesia was replaced by αchloralose. An initial bolus (50 mg/kg, iv) was administered followed by a
continuous infusion (0.017 mL/kg/min of 25 mg/mL, iv). In preliminary
experiments, OP rats required a smaller dose of α-chloralose than predicted from
body weight, and this dose was equivalent to the amount administered to a LF or
OR rat. The level of anesthesia was assessed by the lack of a withdrawal reflex
to a foot pinch. Therefore, the dose of α-chloralose for OP rats was initially
based on a paired LF or OR rat studied on the same day. The α-chloralose
infusion was adjusted as needed by the presence of a withdrawal reflex.
Anesthesia and variables were allowed to stabilize for a minimum of 60 min
before the experiment began.
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Hyperinsulinemic-Euglycemic Clamps
Baseline values of ABP and lumbar SNA were recorded for 20 minutes.
Then, insulin (0.017 mL/kg/min of 220 mU/mL Humulin R dissolved in αchloralose, iv) and a 50% dextrose solution (0.25-1.0 mL/hr, IV) or an equal
volume of 0.9% saline were infused for 120 minutes. This dose of insulin is
equivalent to 3.75 mU/kg/min in 300-350 g Sprague-Dawley rats and has been
previously reported to selectively increase lumbar SNA (Bardgett et al. 2010).
Blood glucose was measured from a drop of arterial blood every 10 minutes
using a standard glucometer (One Touch Ultra). The dextrose infusion rate was
adjusted to maintain euglycemia. Blood (0.2 mL) was collected from the arterial
line into microcentrifuge tubes (3µL, 0.5 mol/L EDTA) at baseline, 60, and 120
minutes. Samples were centrifuged, and plasma was stored at -80oC. Insulin
levels were determined by an ELISA using a commercially available kit
(Millipore).

Data Analysis
All data are expressed as means ± SEM. Changes in integrated SNA are
calculated by subtracting background noise after hexamethonium (30 mg/kg, IV).
For all variables, 60-second segments at each time point were compared to three
60-second baseline period measurements. All data were analyzed by a 1- or 2way ANOVA with repeated measures when appropriate. All post hoc tests were
performed with independent or paired t tests with a layered Bonferroni correction.
A P<0.05 was statistically significant.
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Results
Characteristics of LF, OR, and OP Rats
Initial body weight was not significantly different between LF, OR, or OP
rats (Figure 3). At week 4, OP rats weighed significantly more than LF or OR
rats. The greater weight gain in OP rats was associated with a greater
epididymal and retroperitoneal fat mass (Table 1). Consequently, OP versus LF
or OR rats had a significantly greater adiposity index.

Both ABP and lumbar

SNA were significantly elevated at baseline in OP versus LF and OR rats (Table
1).

Insulin-Induced Sympathoexcitation in LF, OR, and OP Rats
The major goal of this study was to determine whether diet-induced
obesity causes insulin resistance in central sympathetic circuits. To test this
hypothesis, we measured lumbar SNA during a hyperinsulinemic-euglycemic
clamp in LF, OR, and OP rats. Figure 4 illustrates a representative example of
the response in LF, OR, and OP rats. Group data for these responses are
summarized in Figure 5. A hyperinsulinemic-euglycemic clamp significantly
increased lumbar SNA in LF, OR, and OP rats compared to saline infusion. In
fact, the magnitude of this response was not statistically different across groups
at any time.

Blood glucose of LF, OR, and OP did not significantly change from

baseline values despite a significantly lower glucose infusion rate of OP rats
(Figure 5). Although the percent change was not significantly different between
the three groups, the absolute change in lumbar SNA was significantly greater in
OP compared to LF or OR rats (Figure 6). Mean ABP decreased in all three
groups through the 120 min infusion whereas heart rate did not change (data not
shown). Saline infusion had no effect on ABP while it slightly decreased lumbar
SNA equivalently in all groups by 60 min (data not shown).
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As previously reported (Bardgett ME et al. 2010), basal plasma insulin
levels were significantly higher in OP versus LF or OR rats (Table 1, Figure 7A).
At 60 and 120 min, plasma insulin levels of LF versus OP rats were not
statistically different. Plasma insulin levels of OR rats were lower than those of
OP rats. However, the change in plasma insulin levels at 60 and 120 min were
not different across all three groups (Figure 7B). An equivalent change in plasma
insulin resulted in a significantly greater change in lumbar SNA in OP rats.
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Discussion
Previous studies have demonstrated that diet-induced obesity produces
peripheral insulin resistance and a reduction in the central anorexic effect of
insulin (Storlien et al. 1986, Arase et al. 1988, Clegg et al. 2005). However,
insulin also acts within the brain to elevate SNA and alter cardiovascular function
(Bardgett et al. 2010). It was unknown previously whether central sympathetic
circuits were insulin resistant during diet-induced obesity. The present study
demonstrates that a hyperinsulinemic-euglycemic clamp produced similar
increases in OP versus LF or OR rats. These findings suggest that diet-induced
obesity causes a selective insulin resistance in the central nervous system.
In the present study, we utilized a rodent model of diet-induced obesity
characterized by a differential weight gain to a moderate high-fat diet and
segregation into OP and OR rats. This model closely mimics human obesity as
OP rats have elevated cholesterol, hyperinsulinemia, hyperleptinemia, activation
of the renin-angiotensin and sympathetic nervous system, and an elevated ABP
(Boustany et al. 2004, Boustany et al. 2005, Dobrain et al. 2000, Levin et al.
1983, Levin and Keesey 1998). Second, the segregation of OP and OR rats
permits studies to differentiate between the effects of obesity/weight gain versus
consumption of the moderate high-fat diet. In the present study, OP versus LF or
OR rats had a significantly higher body weight, fat pad mass and adiposity index.
In addition, OP versus LF or OR rats had a significantly higher plasma insulin
level, lumbar SNA, and mean ABP.
Using this model, we hypothesized that central sympathetic circuits would
not become insulin-resistant during diet-induced obesity. Despite marked
peripheral insulin resistance as indicated by a significantly lower glucose
utilization of OP versus LF or OR rats, a hyperinsulinemic-euglycemic clamp
produced comparable increases in both plasma insulin levels and lumbar SNA
across all three groups. These findings support the current hypothesis that dietinduced obesity does not affect insulin-sensitive sympathetic circuits.
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Insulin crosses the blood-brain barrier in a transport-mediated process
(Banks 1997). Previous studies have reported insulin transport into the brain
either decreases (Kaiyala et al. 2000, Kern et al. 2006) or does not change
(Israel et al. 1993) in response to diet-induced obesity. Although we did not
measure cerebrospinal insulin levels in LF, OR, and OP rats, a decrease in
insulin transport of OP rats should have resulted in a smaller increase in lumbar
SNA. Since baseline lumbar SNA was significantly higher in OP rats, an
equivalent percent increase in lumbar SNA would suggest that a
hyperinsulinemic-euglycemic clamp produced a larger sympathoexcitatory
response in OP versus LF or OR rats. In contrast, the percent increase in lumbar
SNA was not statistically different across groups. In fact, an equivalent change
in plasma insulin concentration resulted in a significantly greater change in
absolute lumbar SNA when expressed as microvolts. These findings indicate
that diet-induced obesity does not affect insulin transport into brain regions that
contribute to the sympathoexcitatory response.
The present findings differ from previous studies that suggest diet-induced
obesity produces insulin resistance in central neuronal networks. These studies
have reported that diet-induced obesity reduces the anorexic effects of insulin
administered intracerebroventricularly (Carvalheira et al. 2003, Clegg et al. 2005,
Posey et al. 2009). However, the neurons that sense insulin and the
downstream signaling pathways that mediate insulin‟s effects on food intake
versus sympathetic activation have not been fully elucidated. Inhibition of
phosphoinositide 3-kinase prevents the increase in lumbar SNA (Rahmouni et al.
2004) and decrease in food intake (Carvalheira et al. 2003, Niswender et al.
2003) in response to intracerebroventricular administration of insulin.
Furthermore, administration of the melanocortin receptor antagonist SHU9119
prevents the anorexic effect of insulin (Benoit et al. 2002) whereas melanocortin4 receptor knockout mice do not show a sympathoexcitatory response to
intracerebroventricular injection of insulin (Rahmouni et al. 2003). Recently, our
laboratory demonstrated that the sympathoexcitatory response to a
hyperinsulinemic-euglycemic clamp is reversed by blockade of glutamatergic
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receptors in the rostral ventrolateral medulla (Bardgett et al. 2010). Despite this
evidence, it is not clear how or where the central neural pathways diverge to
control food intake versus SNA. The differences between the present findings
and previous studies in regard to insulin resistance in central neuronal pathways
could simply be attributed to different populations of insulin-sensing neurons that
control food intake versus SNA. Clearly, future studies are needed to address
these questions.
Our results are in contrast to some previous findings in humans. The
reasons for the confounding results could be the result of differing methods for
producing hyperinsulinemia or inappropriate insulin levels. Straznicky et al found
that insulin resistant human subjects show a decreased sympathoexcitatory
response to an oral glucose load (Straznicky et al. 2009). In contrast to our
study, they were examining the sympathetic response to an elevation in glucose
as well as insulin and separated subjects based on insulin resistance as opposed
to obesity. In fact, their controls, while insulin sensitive, were in fact obese as
defined by a body mass index >30. Vollenweider et al. performed
hyperinsulinemic-euglycemic clamps in lean and obese subjects. They found a
decreased muscle SNA response to hyperinsulinemia in obese compared to lean
individuals (Vollenweider et al. 1994). Though this is in contrast to our findings,
they also show that lean subjects respond similarly to varying doses of insulin,
the lowest dose producing insulin levels similar to that seen at baseline in obese
subjects. Therefore, it is difficult to gauge whether central insulin resistance or
inappropriate insulin dose results in differences between lean and obese
subjects. The dose of insulin used in our study was determined by previous
studies in our laboratory (Bardgett et al. 2010). This dose is slightly lower than
previous studies but produces plasma insulin levels in lean rats similar to that
seen in diet-induced obese and obese Zucker rats. Due to this dose producing
appropriate plasma insulin levels, we did not feel it necessary to utilize a higher
dose of insulin as that would produce supraphysiologic levels in OP rats.
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The ability of a hyperinsulinemic-euglycemic clamp to produce similar
increases in SNA of LF, OR, and OP rats is reminiscent to previous studies on
selective leptin resistance. Although the anorexic actions of leptin are attenuated
in obesity (Clegg et al. 2005) the renal sympathoexcitatory actions of leptin are
preserved (Rahmouni et al. 2005). Interestingly, only the renal but not lumbar or
brown adipose SNA response to leptin was preserved in obese animals
(Rahmouni et al. 2005). Altogether, this raises the possibility that insulin and
leptin may act through parallel pathways to chronically elevate lumbar and renal
SNA, respectively, in obesity-induced hypertension. In fact, studies in human
populations using microneurography or norepinephrine spillover indicate that
both muscle and renal SNA are elevated in obese individuals (Vaz et al. 1997,
Grass et al. 1995). The relative contribution of insulin versus leptin (or other
factors) to the elevated muscle or renal SNA in obesity-induced hypertension has
not been directly assessed.
In summary, the present findings demonstrate that central sympathetic
circuits are not insulin resistant in diet-induced obesity. Despite pronounced
peripheral insulin resistance of OP rats, a hyperinsulinemic-euglycemic clamp
produced similar increases in lumbar SNA of LF, OR, and OP rats. Together
with previous reports (Morgan and Rahmouni 2010), these findings suggest that
diet-induced obesity produces a selective central insulin resistance. These
findings raise the possibility that hyperinsulinemia may chronically elevate lumbar
SNA in obesity-induced hypertension.

26

Table 1. Characteristics of LF, OR, and OP Rats
Characteristic
Body Weight (g)

LF

OR

OP

581±15

576±11

784±13*

Epididymal

12.5±1.1

14.3±1.2

29.2±1.2*

Retroperitoneal

16.3±3.0

18.2±1.4

38.5±2.2*

Total

28.8±4.1

32.5±2.5

67.7±4.1*

4.9±0.4

5.6±0.4

8.6±0.4*

Fat Pads (g)

Adiposity Index (%)
Plasma insulin (ng/mL)

8.1±1.7

8.4±1.6

15.9±2.3*

Blood Glucose (mg/dL)

56±6

60±4

62±5

ABP (mmHg)

90.8±3.7

93.7±4.5

105.8±5.1*

Lumbar SNA (µV)

1.43±0.26

1.82±0.36

3.62±0.76*

HR (bpm)

408±10

426±9

405±13

Values are mean ± SEM. *Significant difference versus LF or OR (P<0.05).
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Figure 3. Body weight distribution of LF, OR, and OP rats
Body weight as a function of time for LF, OR, and OP rats. n=10 per group.
Values are mean ± SEM. *P<0.05 OP vs LF or OR rats.
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Figure 4. Representative traces from LF, OR, and OP rats during
hyperinsulinemic-euglycemic clamps
Representative examples of ABP, mean ABP, heart rate, and lumbar SNA during
a hyperinsulinemic-euglycemic clamp in (A) LF, (B) OR, and (C) OP rats.
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Figure 5. Summary data during a hyperinsulinemic-euglycemic clamps in
LF, OR, and OP rats
Mean ± SEM of (A) lumbar SNA, (B) mean ABP, (C) glucose infusion rate, and
(D) blood glucose during a hyperinsulinemic-euglycemic clamp in LF (ABP: n=7,
SNA: n=8), OR (ABP: n=8, SNA: n=6), and OP (ABP: n=9, SNA: n=9) rats.
Hyperinsulinemia significantly elevated lumbar SNA in all three groups; however,
the magnitude was not statistically different across groups. * P<0.05 OP vs LF or
OR, # P<0.05 vs baseline.
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Figure 6. Change in lumbar SNA at 60 and 120 min during
hyperinsulinemic-euglycemic clamps of LF, OR, and OP rats
Change in lumbar SNA of LF, OR, and OP rats during a hyperinsulinemiceuglycemic clamp. *P<0.05 OP vs LF or OR rats
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Figure 7. Plasma insulin concentrations during hyperinsulinemiceuglycemic clamps in LF, OR, and OP rats
(A) Plasma insulin concentrations of LF, OR and OP rats at baseline, 60, and
120 min during a hyperinsulinemic-euglycemic clamp. (B) Change in plasma
insulin concentration from baseline of LF, OR and OP rats at 120 min. * P<0.05
OP vs LF or OR, # P<0.05 vs baseline.

Copyright © Megan E. Bardgett 2010
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Chapter III: Glutamatergic Receptor Activation in the Rostral Ventrolateral
Medulla Mediates the Sympathoexcitatory Response to Hyperinsulinemia
This chapter has previously been published: Hypertension. 2010 Feb; 55(2):284290

Specific aim 2 will identify whether glutamate, angiotensin II type 1, or
melanocortin receptors of the RVLM mediate the sympathoexcitatory response to
hyperinsulinemia.

Introduction
Compelling evidence in humans and rodents indicates that elevated
sympathetic nerve activity (SNA) contributes to the pathogenesis of obesityinduced hypertension (Esler et al. 2006, Wofford and Hall 2004). Clinical studies
indicate obese humans have increased norepinephrine spillover (Rumantir et al.
1999, Vaz et al. 1999), elevated muscle SNA (Alvarez et al. 2002, Grassi et al.
1995), and a greater drop in arterial blood pressure (ABP) in response to
ganglionic blockade (Shibao et al. 2007). Similar observations have been
reported in rodent and dog models of obesity (Boustany et al. 2004, Levin 1993,
Stocker et al. 2007). One mechanism postulated to underlie the elevated SNA
and ABP during obesity is hyperinsulinemia (Esler et al. 2006, Wofford and Hall
2004). Clinical studies have revealed a correlation between obesity,
hypertension, and hyperinsulinemia (Esler et al. 2006, Wofford and Hall 2004).
In both humans and rodents, acute hyperinsulinemic-euglycemic clamps
selectively increase muscle or lumbar SNA, respectively (Anderson et al. 1991,
Morgan et al. 1993, Muntzel et al. 1994). These actions are mediated by a
central mechanism because intracerebroventricular administration of insulin
causes a similar selective increase in lumbar SNA (Muntzel et al. 1994). In rats,
chronic hyperinsulinemic-euglycemic clamps increase total peripheral resistance
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and ABP (Brands et al. 1996). However, the neural mechanisms and pathways
that mediate the sympathoexcitatory effects of insulin are poorly understood.
The rostral ventrolateral medulla (RVLM) plays a pivotal role in the
regulation of SNA and ABP (Guyenet 2006). RVLM neurons project to
sympathetic preganglionic neurons of the intermediolateral cell column in the
thoracic and lumbar spinal cord and support basal SNA (Guyenet 2006).
Electrophysiological studies in vivo have identified tonically active, bulbospinal
neurons in the RVLM (Guyenet 2006). The excitability of RVLM neurons is
regulated by a number of neurotransmitters including L-glutamate. Injection of Lglutamate into the RVLM increases neuronal discharge, SNA, and ABP (Guyenet
2006). Blockade of glutamate receptors in the RVLM eliminates many
sympathoexcitatory reflexes (Guyenet 2006) and lowers ABP in multiple
experimental models of hypertension (Ito et al. 2000, Ito et al. 2001,
Bergamaschi et al. 1995). Based on this evidence, we hypothesized that
glutamate receptor activation in the RVLM mediates the sympathoexcitatory
response to hyperinsulinemia.
In addition to glutamate, evidence from several laboratories suggests that
the brain renin-angiotensin and melanocortin systems mediate the
sympathoexcitatory response to insulin. In this regard, RVLM neurons express
Ang II (AT1) receptors (Song et al. 1991), and injection of Ang II into the RVLM
increases SNA and ABP (Dampney et al. 2002). Blockade of brain AT 1 receptors
blunts the pressor response to central hyperinsulinemia (Nakata et al. 1998).
Also, blockade of the renin-angiotensin system prevents insulin-induced
hypertension (Brands et al. 1997). On the other hand, RVLM neurons express
melanocortin receptors, (Adan and Gispen 2000) and injection of a melanocortin
agonist into the RVLM increases SNA and ABP (Kawabe et al. 2006).
Interestingly, the sympathoexcitatory effect to insulin is abolished in melanocortin
4 knockout mice (Rahmouni et al. 2003). Therefore, we hypothesized that one or
both of these systems may contribute to the sympathoexcitatory response during
hyperinsulinemia.
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Materials and Methods
Animals
All of the experimental procedures conform to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by
the University of Kentucky and Pennsylvania State College of Medicine
Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (250350g; Charles River Laboratories) were housed in a temperature controlled room
(22±1oC) with a 14:10-hour light:dark cycle. Rats were fed standard rat chow
and given access to deionized water.

General Procedures
Rats were anesthetized with isoflurane (2-3%) and prepared for
recordings of renal and lumbar SNA and ABP as described previously (Scislo et
al. 1998, Stocker et al. 2005). Animals were artificially ventilated with oxygenenriched room air. End-tidal CO2 and body temperature were maintained at 45% and 37±1oC, respectively. After surgery, anesthesia was replaced by αchloralose (50 mg/kg bolus, 25 mg/kg/hr, IV). The level of anesthesia was
examined by the lack of a withdrawal reflex following a foot pinch. When a stable
level of anesthesia was established, rats were paralyzed with gallamine
triethiodide (20 mg/kg, 0.25 mL/hr, IV). Variables were allowed to stabilize for a
minimum of 30 min before the experiment began.

RVLM Microinjections
RVLM microinjections were performed as described previously in our
laboratory (Adams et al. 2007). Initially, L-glutamate (1 nmol) was injected into
the RVLM at 3 different sites separated by 300 µm in the rostral-caudal plane to
identify the site that produced the largest increase in ABP; subsequent injections
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were performed at these coordinates. For all experiments, injections (60 nL)
were performed over 5 seconds. Injection sites were marked at the end of
experiments with 0.2% rhodamine beads.
Hyperinsulinemic-Euglycemic Clamps
An initial set of experiments was performed to identify a physiological
dose of insulin. Animals were prepared as described above, and insulin (3.75 or
7.5 mU/kg/min, 0.25 mL/hr, IV, Humulin R) and a 50% dextrose solution (0.251.0 mL/hr, IV) were infused for 120 min. Blood glucose was measured from a
drop of arterial blood every 10 min using a standard glucometer (One Touch
Ultra). The dextrose infusion rate was adjusted in order to maintain euglycemia.
Control animals were infused with equal volumes of isotonic saline. Blood
(0.5mL) was collected from the arterial line into microcentrifuge tubes (10 uL, 0.5
M EDTA) at baseline, 60, and 120 min. Samples were centrifuged, and plasma
was stored at -80oC.
For purposes of comparison, plasma insulin levels were analyzed from a
rodent model of diet-induced obesity. Male Sprague-Dawley rats (200-250g,
Charles River Laboratories) were fed a low fat (LF, 10% kcal from fat; Research
Diets, Inc, D12489B) or moderately high fat (32% kcal from fat; Research Diets,
Inc, D12266B) diet for 13 weeks as described previously by our laboratory
(Stocker MD et al. 2007). Those on the high fat diet segregated into obesity
resistant (OR) and obesity prone (OP). Rats were anesthetized and prepared as
described above. Blood samples were collected from the arterial line, and insulin
levels were determined by an ELISA using a commercially available kit
(Millipore).
To determine the contribution of RVLM receptors to the SNA response
during hyperinsulinemia, separate rats were prepared as described above.
Baseline values of ABP, lumbar and renal SNA were recorded for 10 min. Then,
insulin (3.75 mU/kg/min, 0.25 ml/hr, IV) and a 50% dextrose solution (0.25-1.0
ml/hr, IV) were infused for 120 min. At 90 min, one of several compounds was
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bilaterally microinjected into the RVLM: the ionotropic glutamate receptor
antagonist kynurenic acid (KYN, 5 mM), the NMDA receptor antagonist AP5 (5
mmol), the non-NMDA receptor antagonist NBQX (1 mmol), the AT 1 receptor
antagonist losartan (1 nmol), the melanocortin 3/4 receptor antagonist SHU9119
(0.03 nmol), or artificial cerebrospinal fluid (aCSF, 60nL). Doses of various
receptor antagonists were based on previous studies (Kawabe et al. 2006,
Adams et al. 2008, Kiely and Gordon 1994) or preliminary studies in which the
antagonist blocked the sympathetic and pressor responses to the respective
agonist (data not shown).
To determine the time course of action for KYN, animals were prepared as
described above, and the sciatic nerve was stimulated electrically (5 sec train,
500 µA, 20 Hz) before and 10, 20, and 30 min after KYN microinjection into the
RVLM .

Central Insulin Injections
Rats were prepared as described above, and insulin (5, 0.5, 0.05, or
0.0005 µU/nL, 60 nL) was bilaterally microinjected into the RVLM. ABP and SNA
were recorded for 60 min and blood glucose measured every 30 min. The insulin
concentrations were based on previous studies using intracerebroventricular
injection of insulin (Muntzel et al. 1994, Rahmouni et al. 2004) and re-calculated
due to a minimum 10-fold dilution due to the CSF volume of the lateral and 3 rd
ventricles.
In a separate group of rats, intracerebroventricular cannulas were
implanted in the lateral ventricle as described previously (Stocker et al. 2003).
Proper cannula location was verified by a positive drinking test (>3 mL in 30 min)
to angiotensin II (20ng/2µL) (Stocker et al. 2003). Then, rats were prepared as
described above, and insulin (100 mU/2uL) was injected into the lateral ventricle.
This dose of insulin has been repeatedly demonstrated to significantly elevate
lumbar SNA in rodents (Muntzel et al. 1994, Rahmouni et al. 2004). Variables
37

were recorded for 60 min, and blood glucose was measured every 30 min. At
the end of experiments, cannula placement was verified again by the spread of
dye (1% Evan‟s Blue Dye, 2µL) to the 3rd and 4th ventricle.

Western Blot Analysis of Insulin Receptors
RVLM and hypothalamic samples were collected for western blot analysis
at baseline or 60 min after a hyperinsulinemic-euglycemic clamp. Rats were
deeply anesthetized with 5% isoflurane and perfused transcardially with cold
oxygenated aCSF (124 mmol/L NaCl, 26 mmol/L NaHCO3, 0.6 mmol/L
NaH2PO4, 3mmol/L KCl, 1.6 mmol/L MgCl2, 1.5 mmol/L CaCl2, 11 mmol/L
glucose, pH 7.4). The brain was rapidly removed. A chunk of the mediobasal
hypothalamus defined dorsally by the top of the 3rd ventricle, laterally by the
optic tract, rostrally by the optic chiasm, and caudally by the mammillary bodies
was frozen and stored at -80oC. The brainstem was sectioned at 200µm in
oxygenated cerebral spinal fluid (4oC) using a vibratome. The RVLM was isolated
under a microscope, immediately frozen on dry ice and stored at -80oC. Western
blots were performed using a rabbit polyclonal insulin receptor β (IR-β) antibody
(1:1000, C-19; sc-711; Santa Cruz Biotechnology, Inc. Santa Cruz, CA.). The IRβ band intensity for each sample was quantified using NIH ImageJ
(http://rsb.info.nih.gov/nih-image/) and normalized to the respective γ-tubulin
band intensity.
Frozen RVLM or hypothalamus sections were disrupted in 150 µl of
homogenization buffer [1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50
mM NaCl, 400 mM KCl, 25 mM β-glycerophosphate, 50 mM NaF, 5 mM
benzamidine, 20 mM Tris-HCl (pH 7.6), 1 mM EDTA, 1 mM sodium
orthovanadate, 5 mM N-ethylmaleimide, 1 mM PMSF) supplemented with
protease inhibitor cocktail (P8340; Sigma, St Louis, MO)] using a Pyrex PotterElvehjem tissue grinder. To remove any insoluble particulate the tissue
homogenates were centrifuged (10,000 x g, 10 min, 4 °C) and the supernatant
38

transferred to a new microcentrifuge tube. Protein concentration of each sample
was determined using the Bio-Rad DC protein Assay (Hercules, CA) according to
the manufacturer‟s directions. Five micrograms of each sample was precipitated
using the methanol:chloroform procedure and then resuspended in 20 µl of 1X
sample buffer. Samples were prepared for electrophoresis by heating for 5 min at
100 °C. Samples were separated by SDS-PAGE (7.5% gel) and then transferred
to nitrocellulose membrane (0.2 µm) (Bio-Rad, Hercules, CA). The membrane
was incubated in blocking buffer (5% nonfat dry milk in TBS plus 0.1% Tween-20
[TBS-T]) for 1 hr at room temperature and then incubated in blocking buffer
overnight at 4°C with a rabbit polyclonal insulin receptor β (IR-β)antibody
(1:1000, C-19; sc-711; Santa Cruz Biotechnology, Inc. Santa Cruz, CA.). After
the overnight incubation, the membrane was washed (4x, 5min) in TBS-T,
incubated with anti-rabbit horseradish peroxidase (HRP)-conjugated secondary
antibody (1:10,000, 1 hr) at room temperature, incubated in ECL plus for 5 min
(GE Healthcare, Piscataway, NJ) and exposed to X-ray film. To determine
specificity of the IR-β antibody, the membrane was stripped and reprobed with
the IR-β antibody pre-absorbed with five-fold excess of a blocking peptide (sc711P; Santa Cruz Biotechnology, Inc. Santa Cruz, CA.). The membrane was also
stripped and reprobed with a mouse monoclonal γ-tubulin antibody (T6557;
Sigma-Aldrich, St. Louis, MO). The IR-β band intensity for each sample was
quantified using NIH ImageJ (http://rsb.info.nih.gov/nih-image/) and normalized to
the respective γ-tubulin band intensity.

Data Analysis
All data are expressed as mean±SE. Changes in integrated SNA are
calculated by subtracting background noise after hexamethonium (30 mg/kg IV).
For all variables, 30 sec segments at each time point were compared to three 30second baseline period measurements. All data were analyzed by a 1- or 2- way
ANOVA with repeated measures when appropriate. All post hoc tests were
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performed with independent or paired t tests with a layered Bonferonni
correction. A P<0.05 was statistically significant.
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Results
Analysis of Plasma Insulin Levels
Initial experiments were performed to identify an insulin infusion rate which
produced physiological increases in plasma insulin levels. Both infusion rates
significantly increased plasma insulin concentrations at 60 and 120 min (Figure
8). Plasma insulin levels were significantly greater in rats infused with 7.5 vs 3.75
mU/kg/min vs saline infusion.
To compare these infusion rates to a rodent model of obesity, we
analyzed plasma insulin levels from rats maintained on a low-fat or moderate
high-fat diet for 13 weeks. As previously reported (Stocker SD et al. 2007), OP
rats weighed significantly more than LF or OR rats (OP: 793±13g, LF: 612±16g,
OR: 596±8g). The greater body weight of OP rats was associated with a greater
fat pad mass and higher adiposity index than LF or OR rats (Table 2). As
expected, plasma insulin levels were significantly higher in OP versus LF or OR
rats (Figure 8). In fact, plasma insulin levels of OP rats were similar to those rats
infused with 7.5 mU/kg/min and significantly higher than those rats infused with
3.75 mU/kg/min. Plasma insulin levels of LF and OR rats were not different
versus those of rats infused with 3.75 mU/kg/min.

Blockade of Glutamatergic Receptors Reverses Sympathoexcitatory
Response to Insulin
A major goal of this study was to determine whether blockade of
glutamate receptors in the RVLM reversed or attenuated the sympathoexcitation
during hyperinsulinemia. Figure 9 illustrates a representative example of the
responses to a hyperinsulinemic-euglycemic clamp or saline infusion before and
after RVLM microinjection of KYN. Group data are summarized in Figure 10. As
previously reported, hyperinsulinemia selectively increased lumbar SNA (Morgan
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et al. 1993, Muntzel et al. 1994), but did not affect ABP (Figure 9), blood glucose
(Figure 10), renal SNA (data not shown), or heart rate (data not shown).
Microinjection of KYN significantly reduced lumbar SNA in
hyperinsulinemic animals but had no effect in saline-infused animals (Figures 9
and 10). In fact, lumbar SNA was reduced to a level not different from saline
infused animals (P>0.3). At 120 min, lumbar SNA returned to pre-injection
values. Microinjection of aCSF had no effect on any variable in hyperinsulinemic
or control rats (Figure 11). Figure 12 summarizes the peak changes in lumbar
SNA and mean ABP after injection of aCSF or KYN in hyperinsulemic or control
rats. Although the hyperinsulemic-euglycemic clamp did not significantly alter
ABP, microinjection of KYN significantly decreased mean ABP. Microinjection of
KYN or aCSF did not alter renal SNA or heart rate (data not shown).
Since lumbar SNA returned to preinjection values at 30 min after KYN
injection, an additional set of experiments was performed to determine the time
course of ionotropic receptor blockade by KYN. We compared the
sympathoexcitatory response to activation of somatic afferents before and after
RVLM injection of KYN. Prior to blockade, electrical stimulation of sciatic
afferents significantly increased mean ABP, renal SNA, and heart rate (Table 3).
As expected, microinjection of KYN into the RVLM significantly attenuated these
responses at 10 and 20 min. However, the sympathoexcitatory responses at 30
min were not different from baseline responses.

Blockade of NMDA but not non-NMDA Receptors Reverses the
Sympathoexcitatory Response to Insulin
Since blockade of iontotropic glutamate receptors with KYN reversed the
sympathoexcitatory response to insulin, an additional set of experiments was
performed to identify the specific receptor subtype. Microinjection of the NMDA
receptor antagonist AP5 significantly reduced lumbar SNA in hyperinsulinemic
animals (90 min: 142±6% vs peak: 115±9 %, P<0.05). While AP5 did not affect
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absolute values of mean ABP (90 min: 128±7 vs peak: 121 ±7 mmHg), AP5 did
cause a significant drop in mean ABP (Figure 12). Interestingly, the fall in lumbar
SNA and mean ABP of hyperinsulinemic rats was similar between KYN and AP5
(Figure 12). In contrast, microinjection of the non-NMDA receptor antagonist
NBQX did not affect lumbar SNA (90 min: 142±12 vs peak: 148± 13 %) or mean
ABP (90 min: 105± 7 vs peak: 110± 6 mmHg). AP5 and NBQX did not affect
lumbar SNA or ABP in saline-infused animals.

RVLM AT 1 and Melanocortin Receptors Do Not Mediate Insulin-Induced
Sympathoexcitation
In contrast to blockade of glutamate receptors, microinjection of the AT 1
receptor antagonist losartan or the melanocortin receptor antagonist SHU9119
did not affect the sympathoexcitatory response to hyperinsulinemia. Peak
changes in lumbar SNA and ABP after microinjection of losartan or SHU9119 are
illustrated in Figure 13. As expected, the hyperinsulinemic-euglycemic clamp
significantly increased lumbar SNA at 90 min (P<0.01) but did not change mean
ABP, renal SNA, or heart rate (data not shown). Microinjection of losartan did
not decrease lumbar SNA (90 min: 138±12 vs peak: 147±12 %) or mean ABP
(90 min: 111±8 vs peak: 120±8 mmHg). Similarly, microinjection of SHU9119 did
not decrease lumbar SNA (90 min: 134±8 vs peak: 147±17 %) or mean ABP (90
min: 96±6 to peak: 109±5 mmHg). Losartan and SHU9119 did not affect lumbar
SNA or ABP in saline-infused animals (data not shown).

Insulin Receptor Expression and Insulin Microinjection in the RVLM
To determine whether insulin may act directly in the RVLM to increase
SNA, we analyzed insulin receptor expression and sympathetic responses to
microinjection of insulin in the RVLM. Insulin receptor expression was
significantly lower in the RVLM compared to the ventromedial hypothalamus
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(Figure 14A). In fact, the IR-β band in RVLM samples was virtually absent
(Figure 14A) and was not altered by a hyperinsulinemic-euglycemic clamp (data
not shown).
RVLM microinjection of insulin at any dose did not alter lumbar SNA or
ABP (Figure 14B). In marked contrast, injection of insulin into the lateral ventricle
significantly increased lumbar SNA. Plasma glucose levels were not altered by
RVLM or lateral ventricle injection of insulin (data not shown).
Histology
All injection sites were centered in the RVLM defined as the triangular
region located 0 to 600 µm caudal to the caudal pole of the facial nucleus and
bordered dorsally by nucleus ambiguous, medially by the inferior olive or
pyramidal tracts, and laterally by the spinal trigeminal nucleus (Figure 15).
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Discussion
Previous studies have demonstrated that hyperinsulinemic-euglycemic
clamps produce non-uniform increases in SNA (Anderson et al. 1991, Morgan et
al. 1993, Anderson et al. 1992). However, the neural mechanisms or brain
regions by which insulin acts to selectively increase lumbar SNA have not been
identified. The present study provides several novel findings: 1) a
hyperinsulinemic clamp with physiological increases in plasma insulin levels
elevated lumbar SNA, 2) blockade of glutamatergic, and more specifically NMDA,
receptors reversed the sympathoexcitatory effects of hyperinsulinemia, 3)
blockade of RVLM AT1 or melanocortin 3/4 receptors did not affect the
sympathoexcitatory response to insulin, 4) the RVLM has a low expression of
insulin receptors, and 5) microinjection of insulin into the RVLM did not elevate
lumbar SNA. Collectively, these findings suggest insulin activates a NMDAdependent glutamatergic pathway to the RVLM to increase lumbar SNA.
To identify a physiologically relevant dose of insulin, we compared plasma
insulin levels between control rats infused with insulin versus diet-induced obese
rats. This model of diet-induced obesity has similar characteristics to obese
humans such as activation of the renin-angiotensin system, hyperleptinemia,
hyperinsulinemia, elevated sympathetic outflow, and hypertension (Boustany et
al. 2004, Boustany et al. 2005, Dobrian et al. 2000, Levin and Keesey 1998,
Levin 1983). Indeed, the plasma insulin levels of control rats infused with 3.75
mU/kg/min were significantly lower than those of OP rats. Although there was no
difference between LF or OR rats versus control rats infused with 3.75
mU/kg/min, LF and OR rats were 13-15 weeks older and had a greater fat pad
mass and higher adiposity index than the control rats. Additional data indicate
that plasma insulin levels in obese Zucker rats (13-15 weeks) are not different
from those of control rats infused with 3.75 mU/kg/min (Table 4). Collectively,
these data indicate that the insulin infusion rate in the present study is
physiologically relevant. Whether the elevation in circulating insulin contributes
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to the elevated sympathetic outflow and hypertension in these rodent models of
obesity is unknown.

Glutamate neurotransmission in the RVLM mediates a number of
sympathoexcitatory reflexes including the responses to hypoxia and activation of
somatic afferents (Guyenet 2006). Blockade of RVLM ionotropic glutamate
receptors also lowers ABP in a number of experimental models of hypertension
associated with elevated sympathetic outflow (Ito et al. 2000, Ito et al. 2001,
Bergamaschi et al. 1995). In the present study, RVLM injection of KYN, but not
losartan or SHU 9119, completely reversed the sympathoexcitatory response to
hyperinsulinemia. Although lumbar SNA returned to preinjection levels at 30 min
after KYN injection, this response is consistent with the time course of ionotropic
receptor blockade with KYN. These findings support two important conclusions:
1) insulin activates the brain renin-angiotensin and melanocortin systems outside
the RVLM (ie, hypothalamus), and 2) ionotropic glutamate receptors in the RVLM
mediate the sympathoexcitatory actions to hyperinsulinemia. Subsequent
experiments clearly demonstrate that NMDA receptors solely mediate this
response. The ability of KYN or AP5 to reverse the sympathoexcitatory effects of
hyperinsulinemia cannot be attributed to a direct modulatory role of insulin within
the RVLM as insulin receptor expression is low, and direct injection of insulin into
the RVLM did not alter lumbar SNA and ABP. Therefore, insulin activates a
glutamatergic NMDA-dependent pathway to the RVLM to elevate SNA.
The origin of the insulin-driven glutamatergic pathway to the RVLM is not
known. The sources of glutamatergic input to the RVLM have not been
completely identified; however, the RVLM is densely innervated by glutamatergic
neurons in the hypothalamic paraventricular nucleus (Stocker et al. 2006).
Interestingly, preliminary data from our laboratory indicate that inhibition of the
hypothalamic paraventricular nucleus reverses the sympathoexcitatory response
to hyperinsulinemia (Stocker et al. 2007). Although previous studies have
reported insulin receptor binding in the hypothalamic paraventricular nucleus
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(Werther et al. 1987), it is not known whether insulin acts directly on these
neurons or elsewhere to elevate SNA. A number of other hypothalamic
structures also express insulin receptors including the arcuate nucleus,
ventromedial hypothalamus, and circumventricular organs of the forebrain lamina
terminalis (Werther et al. 1987). However, there are no available studies that
have systemically examined the contribution of these various structures to the
sympathoexcitatory response to insulin and whether such neurons detect
circulating insulin. To date, previous studies have demonstrated that either
global inhibition of hypothalamic PI3K (Rahmouni et al. 2004) or lesion of the
anteroventral third ventricular region (Muntzel et al. 1994) attenuates the
increase in lumbar SNA during hyperinsulinemia. Clearly, future experiments are
needed to identify the neurons that detect changes in circulating insulin and how
this translates into activation of a glutamatergic pathway to the RVLM to increase
lumbar SNA.
In summary, the present study provides the first evidence of a specific
brain region that mediates the sympathoexcitatory response to hyperinsulinemia.
The results clearly demonstrate the sympathoexcitatory response to insulin
depends upon activation of glutamatergic, and more specifically NMDA,
receptors in the RVLM. Insulin likely acts at hypothalamic sites to increase
glutamatergic drive to the RVLM as these neurons express a low level of insulin
receptors and direct injection of insulin into the RVLM did not alter lumbar SNA or
ABP.

Perspectives
Clinical studies have revealed a correlation between obesity, hypertension, and
hyperinsulinemia (Esler et al. 2006, Wofford and Hall 2004), but the role of insulin
in hypertension remains controversial. In rats, acute hyperinsulinemia elevates
lumbar SNA, and chronic hyperinsulinemic-euglycemic clamps increase total
peripheral resistance and ABP (Morgan et al. 1993, Muntzel et al. 1994). In
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contrast, studies performed in dogs have reported that peripheral infusion of
insulin did not elevate ABP (Brands et al. 1991, Hildebrandt et al. 1999). The
discrepancy between data from rats versus dogs may be explained by greater
peripheral insulin sensitivity in dogs. Consistent with this notion, a
hyperinsulinemic-euglycemic clamp in dogs increased, rather than decreased,
cardiac output thereby indicating a systemic vasodilatory response and no
change in ABP (Brands et al. 1991). Unfortunately, it is not known whether dogs
exhibit a similar sympathoexcitatory response to insulin as previously reported in
mice (Rahmouni et al. 2004, Rahmouni et al. 2004), rats (Morgan et al. 1993,
Muntzel et al. 1994), and humans (Anderson et al. 1991, Anderson et al. 1992).
Due to the absence of experimental tools to directly assess the contribution of
insulin to these chronic diseases, the role of insulin in obesity-related
hypertension or other disease states of hyperinsulinemia will likely remain
controversial. Yet, the present findings provide a potential model to examine the
pathways and mechanisms that may contribute or support the elevated SNA
during obesity-related hypertension.
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Table 2. Characteristics for LF, OR, and OP rats

Group

Characteristic

LF

OR

OP

Initial Body Weight, g

221±7

233±2

245±4*

Final Body Weight, g

612±16

596±8

793±13*

Epididymal, g

14±1

16±1

28±1*

Retroperitoneal, g

20±3

21±1

38±2*

Total, g

34±4

36±3

67±3*

5.5±0.6

6.1±0.4

Fat Pads

Adiposity Index, %

8.4±0.4*

Values are mean ± SEM. *Significant difference versus LF or OR rats (P<0.05).
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Table 3. Effect of Ionotropic Receptor Blockade on the Sympathoexcitatory
Reflex to Activation of Somatic Afferents
___________________________________________________________

Stimulation Time

Characteristic

Baseline

10 min

20 min

30 min

___________________________________________________________

∆ Mean ABP

31±4

1±4 *

6±4 *

23±6

66±15

7±6 *

26±9 *

39±9

1±1 *

5±2 *

13±3

(mmHg)

∆ Renal SNA (%)

∆ Heart Rate (BPM) 14±2

___________________________________________________________
Values are mean ± SEM and represent changes in mean ABP, SNA, and heart
rate during electrical stimulation of sciatic afferents. KYN was bilaterally injected
into the RVLM at time = 0. Note that the sympathoexcitatory response was
attenuated at 10 and 20 min after KYN injection but returned at 30 min.
*Significant difference vs baseline values microinjection into the RVLM, P<0.05.
Baseline mean ABP: 133±1 mmHg, baseline heart rate: 426±4 beats per minute,
n=5
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Table 4. Characteristics of Lean and Obese Zucker Rats

Characteristic

Lean

Obese

Age, weeks

15.3±0.5

15.8±0.4

Body Weight, g

376±9

564±21*

Insulin, ng/mL

1.1±0.2

10.5±3.5*

Values are mean ± SEM. *Significant difference versus lean (P<0.05).

Plasma insulin levels were analyzed from samples of lean and obese Zucker rats
generously provided by Dr. David Stepp (Medical College of Georgia). Half the
rats were fasted overnight and rats were anesthetized with isoflurane,
decapitated, and trunk blood collected. Insulin levels were determined by an
ELISA using a commercially available kit (Millipore).
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Figure 8. Plasma insulin concentrations during a hyperinsulinemiceuglycemic clamp compared to plasma insulin concentrations from LF, OR,
and OP rats.
Plasma insulin concentrations at baseline, 60, and 120 min during a
hyperinsulinemic-euglycemic clamp (3.75 mU/kg/min, n=9; 7.5 mU/kg/min, n=3)
or saline infusion (n=3). Plasma insulin concentrations from LF (n=5), OR (n=5)
and OP (n=6) rats were analyzed for purposes of comparison. Plasma insulin
levels were not different between OP rats and control rats infused with 7.5
mU/kg/min. *Significant difference vs baseline levels (P<0.05), †Significant
difference versus 3.75 mU/kg/min (P<0.05), ‡Significant difference versus LF
and OR rats (P<0.05).
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Figure 9. KYN significantly decreases SNA and ABP during
hyperinsulinemic-euglycemic clamp
Representative examples of ABP, mean ABP, and lumbar SNA during RVLM
microinjection of KYN in rats receiving a (A) hyperinsulinemic-euglycemic clamp
or (B) saline infusion. Traces for raw lumbar SNA represent (a) baseline, (b)
peak infusion, and (c) post-KYN injection.
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Figure 10. Summary data of rats receiving saline or insulin infusion during
RVLM microinjection of KYN
Summary data of lumbar SNA, mean ABP and blood glucose during RVLM
microinjection of KYN ( ) in rats receiving a hyperinsulinemic-euglycemic clamp
( , n=5) or saline infusion (

n=5). Injection of KYN significantly reduced lumbar

SNA in rats receiving a hyperinsulinemic clamp but had no effect in those
receiving saline infusion. *Significant difference vs saline infused-rats (P<0.05),
†Significant difference vs pre-injection or 90-min value (P<0.05).
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Figure 11. Summary data of rats receiving saline or insulin infusion during
RVLM microinjection of aCSF
Summary figures of lumbar, mean ABP, and blood glucose during 120-minute
hyperinsulinemic-euglycemic clamp or saline infusion.
and

Insulin + aCSF (n=7)

saline + aCSF (n=3). *Significant difference vs saline (P<0.05)
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Figure 12. Peak changes in lumbar SNA and mean ABP after glutamate
receptor blockade
Peak changes in lumbar SNA and mean ABP after bilateral microinjection of
aCSF, KYN, AP5, or NBQX into the RVLM during a saline infusion (n=3-7 per
group) or hyperinsulemic-euglycemic clamp (n=3-7 per group). *Significant
difference vs rats infused with saline within same drug treatment or rats infused
with insulin + aCSF (P<0.05)
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Figure 13. Peak changes in lumbar SNA and mean ABP after drug
microinjection into RVLM
Peak changes in lumbar SNA and mean ABP after bilateral microinjection of
aCSF, KYN, losartan, or SHU 9119 into the RVLM during a saline infusion (n=4-9
per group) or hyperinsulinemic-euglycemic clamp (n=3-6 per group). * Significant
difference vs rats infused with saline within same drug treatment or rats infused
with insulin + aCSF (P<0.05)
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Figure 14. Insulin receptor concentration in the RVLM and lumbar SNA
response to RVLM insulin microinjection
(A) Examples of western blot analysis for insulin receptor β and γ-tubulin in the
hypothalamus (H) and RVLM (R). Insulin receptor β expression as a ratio to γtubulin was significantly lower in the RVLM versus the hypothalamus (n=4 per
group, *P<0.01). (B) Change in lumbar SNA and ABP after injection of insulin into
the RVLM (n=3-4 per group) or lateral ventricle (n=5). *Significant difference
versus aCSF or 0 insulin (P<0.01)
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Figure 15. Microinjection sites of KYN and aCSF into the RVLM
Schematic drawings of RVLM injection sites (
saline + KYN, and

Insulin + KYN,

insulin + aCSF,

saline + aCSF). Microinjections of AP5, NBQX, losartan

and SHU9119 were similar in location (data not shown). Sections represent 11.6 mm (top) and -11.9 mm (bottom) in reference to bregma. IO indicates
inferior olive; p, pyramidal tracts; NA, nucleus ambiguous; ST, spinal trigeminal
nucleus

Copyright © Megan E. Bardgett 2010

59

Chapter IV: Obesity-Induced Hypertension Depends on Glutamatergic
Neurotransmission in the Rostral Ventrolateral Medulla

Specific aim 3 will examine whether glutamate, angiotensin II type 1, or
melanocortin receptors of the RVLM are involved in the development of dietinduced obesity hypertension.

Introduction
Obesity is a major risk factor for the development of hypertension, type II
diabetes, and cardiovascular disease (Izzo et al. 2008, van Dieren et al. 2010).
In fact, the Framingham Heart Study suggests that adiposity is the number one
potentially modifiable risk factor predetermining individuals for hypertension
(Garrison et al. 1987). Strong evidence indicates that activation of the
sympathetic nervous system leads to the etiology of obesity-induced
hypertension (Esler et al. 2006, Wofford and Hall 2004). Obese humans have
increased norepinephrine spillover to the kidneys and vasculature (Grassi et al.
1985, Vaz et al. 1997) as well as elevated muscle sympathetic nerve activity
(SNA) when measured by microneurography (Grassi et al. 1995, Lambert et al.
2007). In addition, ganglionic blockade lowers arterial blood pressure (ABP) to a
greater extent in obese hypertensive subjects compared to lean subjects (Shibao
et al. 2007) and similar evidence was found in animal models of obesity
hypertension (Truett et al. 1996, D‟Angelo et al. 2006). Diet-induced obese rats
have elevated urinary catecholamines while renal denervation in obese dogs
prevents the development of hypertension (Levin 1993, Kassab et al. 1995).
Although elevated SNA has been implicated in obesity-induced hypertension,
little is known about the central circuits involved in maintaining ABP and SNA in
obesity.
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Our laboratory demonstrated that inhibition of the rostral ventrolateral
medulla (RVLM) caused a significantly greater fall in ABP in obese hypertensive
rats compared to controls highlighting a dominant role for the RVLM (Stocker et
al. 2007). The RVLM plays a pivotal role in regulating SNA and ABP (Guyenet
2006). RVLM neurons are tonically active and send direct projections to
preganglionic neurons of the intermediolateral cell column in the thoracic and
lumbar spinal cord which control basal levels of ABP and SNA (Guyenet 2006).
The excitability of RVLM neurons is mediated by a number of neurotransmitters
including L-glutamate. Microinjection of glutamate into the RVLM increases both
SNA and ABP (Ross et al. 1984, Bennaroch et al. 1986) while glutamate receptor
blockade eliminates a number of sympathoexcitatory reflexes (Granata et al.
1985, Stornetta et al. 1989, Koshiya et al. 1993) as well as lowering blood
pressure in multiple experimental models of hypertension (Bergamaschi et al.
1995, Ito et al. 2000, Ito et al. 2001). In fact, our laboratory recently
demonstrated that RVLM glutamatergic receptors are responsible for the
elevated lumbar SNA during hyperinsulinemia (Bardgett et al. 2010).
A number of other neurotransmitter systems are implicated in maintaining
elevated SNA and ABP in obesity. One such system is the renin-angiotensin
system. The major components of the renin-angiotensin system are elevated in
obese humans and rodents. Blockade of the renin-angiotensin system in obesehypertensive humans lowers ABP (Grassi et al. 2003, Bechir et al. 2005) while
treatment of diet-induced obese rats with an AT1 receptor antagonist significantly
lowers ABP (Boustany et al. 2005). In addition, studies indicate a role for the
melanocortin system. Melanocortin-4-receptor knockout mice are obese yet do
not develop hypertension (Tallam et al. 2005) and show no sympathoexcitatory
response to insulin or leptin (Benoit et al. 2002). As well, blockade of central
melanocortin receptors lowers ABP in spontaneously hypertensive rats (da Silva
et al. 2008). Given that the RVLM expresses both angiotensin II type 1 (AT 1) and
melanocortin 3/4 receptors (Adan and Gispen 1997, Adan and Gispen 2000,
Song et al 1991) and activation of either receptor increases ABP and SNA in

61

rodents (Dampney et al. 2002, Kawabe et al. 2006) we hypothesized that one or
both systems may play a role in diet-induced obesity hypertension.
The goal of this study was to elucidate the neural circuits, and specifically
to examine the role of multiple neurotransmitter systems in the RVLM, mediating
ABP and lumbar SNA in obesity-hypertension. On the basis of previous findings,
we hypothesized that RVLM glutamatergic receptors would be responsible for
maintaining the elevated ABP and SNA associated with diet-induced obesity.
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Materials and Methods

Animals

All of the experimental procedures were approved by the Penn State
University Institutional Animal Care and Use Committee and were conducted in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Male Sprague-Dawley rats (Charles River Laboratory)
weighing 150 to 200 g were housed in a temperature-controlled room (22o-23o C)
with a 14-hour/10-hour light-dark cycle (light on at 7:00 AM). Rats were placed
on a LF diet (10% kcal from fat; Research Diets, Inc. D12489B) or a moderate
high-fat diet (32% kcal from fat, Research Diets, Inc. D12266B) for 13 weeks.
After 5 weeks, rats fed the moderately high-fat diet segregated into OP and OR
based on body weight distribution as described previously (Stocker et al. 2007).
Briefly, a body weight histogram was constructed and resulted in a distribution of
rats into OP and OR groups corresponding with the upper and lower one third of
rats, respectively.
Rats were anesthetized with isoflurane (2%-3%, 100% O2) and prepared
for recordings of lumbar SNA and ABP as described previously (Scislo TH et al.
1998, Stocker et al. 2005). Animals were artificially ventilated with oxygenenriched room air. End-tidal CO2 and body temperature were maintained at 4%
to 4.5% and 37±1o C, respectively. After surgery, anesthesia was replaced by αchloralose. An initial bolus (50 mg/kg, iv) was administered followed by a
continuous infusion (0.017 mL/kg/min of 25 mg/mL, iv). In preliminary
experiments, OP rats required a smaller dose of α-chloralose than predicted from
body weight, and this dose was equivalent to the amount administered to a LF or
OR rat. The level of anesthesia was assessed by the lack of a withdrawal reflex
to a foot pinch. Therefore, the dose of α-chloralose for OP rats was initially
based on a paired LF or OR rat studied on the same day. The α-chloralose
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infusion was adjusted as needed by the presence of a withdrawal reflex.
Anesthesia and variables were allowed to stabilize for a minimum of 60 min
before the experiment began.

RVLM Microinjections
RVLM microinjections were performed as described previously in our
laboratory (Adams et al. 2007). Initially, L-glutamate (0.1 nmol) was injected into
the RVLM at 3 different sites separated by 300 µm in the rostral-caudal plane to
identify the site that produced the largest increase in ABP; subsequent injections
were performed at these coordinates. For all experiments, injections (60 nL)
were performed over 5 seconds. Injection sites were marked at the end of
experiments with 0.2% rhodamine beads.
Baseline values of ABP and lumbar were recorded for 20 minutes. Then
the glutamate receptor antagonist kynurenic acid (25 mM), the AT1 receptor
antagonist losartan (1 nmol), the melanocortin receptor antagonist SHU 9119
(0.5 mmol/L), or the control artificial cerebrospinal fluid (60nL) were bilaterally
microinjected into the RVLM. Variables were then recorded for another 45
minutes. Doses of various receptor antagonists were based on previous studies
(Bardgett et al. 2010, Kawabe et al. 2006, Adams et al. 2008, Kiely and Gordon
1994).

Data Analysis
All data are expressed as means ± SEM. Changes in integrated SNA are
calculated by subtracting background noise after hexamethonium (30 mg/kg, IV).
For all variables, 60-second segments at each time point were compared to three
60-second baseline period measurements. All data were analyzed by a 1- or 2way ANOVA with repeated measures when appropriate. All post hoc tests were
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performed with independent or paired t tests with a layered Bonferroni correction.
A P<0.05 was statistically significant.
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Results

Characteristics of LF, OR, and OP Rats
Initial body weights were not different between LF, OR, or OP rats (Figure 16).
By 4 weeks, OP rats weighed significantly more than either LF or OR rats. This
greater weight gain was associated with increased epididymal and
retroperitoneal fat mass and consequently an elevated adiposity index (Table 5).

Blockade of Glutamate Receptors Lowers ABP and SNA in OP Rats
The major goal of this study was to determine whether blockade of glutamate
receptors significantly attenuated ABP or SNA in diet-induced obese,
hypertensive rats. Figure 17 illustrates a representative trace from a LF, OR, and
OP rat before and after blockade of RVLM glutamatergic receptors. Group data
are summarized in Figure 18. As previously reported (Stocker et al. 2007) OP
rats had significantly elevated ABP compared to LF or OR rats (Figure 18A).
KYN microinjection into the RVLM significantly lowered ABP and lumbar
SNA in OP rats but had no effect in either LF or OR rats (Figure 17 and 18).
ABP was decreased to a level not significantly different than that seen in LF and
OR rats. Microinjection of aCSF had no effect on ABP or SNA in any group.
Figure 18 C, D summarize the peak changes in ABP and lumbar SNA after
injection of aCSF or KYN in LF, OR, and OP rats.

RVLM AT 1 and Melanocortin 3/4 Receptors Do Not Mediate the Elevated
ABP in Obesity
In contrast to blockade of glutamate receptors, microinjection of the angiotensin II
type 1 receptor antagonist losartan or the melanocortin receptor antagonist SHU
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9119 into the RVLM had no effect on ABP or lumbar SNA in LF, OR, or OP rats.
Figures 19 and 20 illustrate representative traces from a LF, OR, and OP rat
before and after blockade of AT1 and melanocortin 3/4 receptors, respectively.
Peak changes in ABP and lumbar SNA after losartan or SHU 9119 injection are
shown in Figure 21. Changes were not significantly different compared to aCSF
injection. As expected, ABP was significantly elevated in OP rats compared to
LF or OR rats in both groups. Microinjection of losartan did not affect ABP in LF
(Baseline: 91±2 mmHg vs peak: 94±4 mmHg), OR (Baseline: 88±2 mmHg vs
peak: 90±4 mmHg), or OP (Baseline: 103±2 mmHg vs peak: 107±3 mmHg) rats
or lumbar SNA in LF (Baseline: 99±1% vs Peak: 98±1%), OR (Baseline: 100±2%
vs peak: 98±3%), or OP (Baseline: 100±1% vs peak: 114±8%) rats. Similarly,
microinjection of SHU 9119 did not affect ABP in LF (Baseline: 91±3 mmHg vs
peak: 95±3 mmHg), OR (Baseline: 86±2 mmHg vs peak: 95±2 mmHg), or OP
(Baseline: 103±3 mmHg vs peak: 107±3 mmHg) or lumbar SNA in LF (Baseline:
99±1% vs peak: 112±7%), OR (Baseline: 98±2% vs peak: 102±2%), or OP
(Baseline: 98±1% vs peak: 102±3%) rats.

Glutamate Receptor Activation
Microinjection of L-glutamate (0.1 nmol) significantly elevated ABP and lumbar
SNA in LF, OR, and OP rats (Figure 22). The increase in ABP and lumbar SNA
were not significantly different between groups.

Histology
All injection sites were centered in the RVLM defined as the triangular region
located 0 to 600 µm caudal to the caudal pole of the facial nucleus and bordered
dorsally by nucleus ambiguous, medially by the inferior olive or pyramidal tracts,
and laterally by the spinal trigeminal nucleus (Figure 23).
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Discussion
Previous studies have demonstrated that obesity results in elevated SNA
and ABP (Alvarez et al. 2002, Grassi et al. 1995, Lambert et al. 2007). Our
laboratory previously demonstrated that the RVLM mediates this elevation as
inhibition of RVLM neurons produced a greater fall in ABP in OP rats compared
to LF or OR rats (Stocker et al. 2007). However, the neural mechanisms through
which diet-induced obesity causes increased activation of RVLM neurons was
previously unknown. The present study illustrates that diet-induced obesity
hypertension depends on glutamatergic transmission through the RVLM.
The present study assessed the contribution of multiple RVLM receptor
systems to the elevation in SNA and ABP in diet-induced obesity. We utilized a
rodent model of diet-induced obesity that has previously been shown to result in
segregation into OP and OR rats based on differential weight gain. This model
provides multiple benefits: it closely emulates human obesity and allows
differentiation between effects of obesity/weight gain versus consumption of the
moderate high-fat diet. In comparison to human obesity, OP rats have elevated
cholesterol, hyperinsulinemia, hyperleptinemia, activation of the reninangiotensin and sympathetic nervous system, and elevated ABP (Boustany et al.
2004, Levin et al. 1983, Dobrain et al. 2000, Levin and Keesey 1998) due to their
increased caloric intake compared to OR rats. In the present study, similar to
what we have seen previously, OP rats had a significantly higher body weight, fat
pad mass, adiposity index, and mean ABP.
The RVLM is the major vasomotor center with direct projections to the
intermediolateral cell column of the thoracic and lumbar spinal cord. Tonic
activity of RVLM neurons is known to be responsible for maintaining baseline
ABP. The contribution of RVLM neurons to maintaining baseline SNA and ABP
is maintained by a balance of excitatory and inhibitory inputs; and it is postulated
that hypertension is a result of a shift in the balance between these excitatory
and inhibitory inputs to the RVLM. In support of this notion, blockade of RVLM
glutamatergic receptors lowers ABP in a number of experimental models of
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hypertension. As well, our laboratory recently demonstrated that the elevation in
lumbar SNA associated with hyperinsulinemia is dependent on RVLM glutamate
receptors (Bardgett et al. 2010). Here, we demonstrate that glutamate
neurotransmission in the RVLM is necessary for diet-induced obesity
hypertension. Blockade of ionotropic glutamate receptors, using a dose of KYN
we previously showed to be sufficient to eliminate the somatic pressor response
(Bardgett et al. 2010), lowers lumbar SNA and ABP in OP rats compared to LF or
OR rats. In addition, following glutamate receptor blockade, ABP in OP rats was
not significantly different from that in LF or OR rats. From this study, it is unclear
whether this response is mediated solely through NMDA vs non-NMDA RVLM
glutamate receptors. Future studies will be needed in order to determine if it is
specific for one or the other but given that the sympathoexcitatory response to
hyperinsulinemia was mediated solely through NMDA-glutamate receptors it
could be hypothesized that obesity-induced hypertension may also rely on NMDA
receptors.
In contrast to the role of RVLM glutamate receptors, this study
demonstrated that neither RVLM AT1 nor melanocortin 3/4 receptors mediate
diet-induced obesity hypertension. Blockade of the renin-angiotensin system has
been shown to reverse or block the development of obesity-induced hypertension
(Brands et al. 1997, Boustany et al. 2005). In previous studies, blockade
occurred systemically and it is therefore possible that renin-angiotensin system
activation plays a more pivotal role in the periphery as compared to centrally. In
contrast to the renin-angiotensin system, the roles of melanocortin 3/4 receptors
have been implicated centrally. Given that melanocortin 3/4 receptor blockade
reverses the elevated ABP in spontaneously hypertensive rats and that
melanocortin-4 receptor knockout mice are obese yet not hypertensive it can be
hypothesized that the melanocortin system is activated centrally but not in the
RVLM. The hypothalamic paraventricular nucleus has projections to the RVLM
as well as direct projections to the intermediolateral cell column. Stimulation of
the hypothalamic paraventricular nucleus causes an elevation in SNA and ABP.
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Therefore, it is possible that either the renin-angiotensin system or melanocortin
system may be acting at the level of the hypothalamic paraventricular nucleus.
The pressor response to L-glutamate microinjection into the RVLM was
not significantly different between LF, OR, or OP rats. It can therefore be
inferred that diet-induced obesity does not result in an increased responsiveness
of these neurons to L-glutamate. A greater response to L-glutamate has been
demonstrated in rats placed on a high salt diet which was concluded to be the
result of increased excitability of RVLM neurons. (Adams et al. 2007) In contrast
to those studies, the pressor response in LF, OR, and OP rats was similar. It is
not possible to completely rule out a change in concentration of RVLM glutamate
receptors but one would expect a greater pressor response if glutamate receptor
concentration was elevated in OP rats.
Blockade of glutamate receptors under normotensive conditions does not
cause a decrease in SNA or ABP. This is hypothesized to occur because KYN
equally blocks both an excitatory and inhibitory drive to the RVLM. In the case of
obesity-induced hypertension, what is normally an equal balance is shifted to a
greater excitatory drive. This change could be due to an increase in excitatory
input or a decrease in inhibitory input to the RVLM. If the shift in a greater
excitatory input to the RVLM was due to a decrease in the inhibition of RVLM
neurons you would expect to see a greater increase in SNA and ABP during
glutamate microinjection. This is based on the findings of Ito and Sved who
showed that disruption of the inhibitory pathway to RVLM results in significantly
greater pressor responses to glutamate stimulation (Ito and Sved 1997).
Obesity is associated with a number of altered characteristics including
hyperinsulinemia, hyperleptinemia, insulin resistance, activation of the reninangiotensin system, and dysfunction of the baroreceptor reflex. All of these
factors are hypothesized to play a role in activation of the sympathetic nervous
system and elevation of ABP in diet-induced obesity. From this study it is not
possible to ascertain the role of these numerous characteristics. Future studies
will be needed to try and determine specifically which characteristics of obesity
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lead to activation of the sympathetic nervous system and subsequent elevation in
ABP.
In summary the present findings identify a specific brain region and
receptor system involved in mediating obesity-induced hypertension. The results
clearly indicate that RVLM glutamatergic receptors are involved in maintaining
lumbar SNA and ABP in OP rats. It is also evident that neither RVLM AT1 nor
melanocortin 3/4 receptors mediate obesity-induced hypertension.
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Table 5. Characteristics of LF, OR, and OP Rats
Characteristic

LF

OR

559±14

577±8

746±18*

Epididymal

12.3±1.3

14.3±0.7

23.8±1.9*

Retroperitoneal

12.2±1.2

13.8±0.7

26.8±1.9*

Total

24.5±2.4

28.1±1.2

50.7±4.4*

Adiposity Index (%)

4.3±0.4

4.9±0.2

6.7±0.4*

Body Weight (g)

OP

Fat Pads (g)

_____________________________________________________________
Values are mean ± SEM. *Significant difference versus LF or OR (P<0.05).
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Figure 16. Body Weight Distribution for LF, OR, and OP rats
Body weight as a function of time for LF, OR, and OP rats. Values are
Mean ±SEM. n=13 per group. *Significant difference between OP vs LF or OR
rats (P<0.05)
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Figure 17. Representative traces of ABP and lumbar SNA from LF, OR, and
OP rats before and after KYN microinjection into the RVLM
Representative examples of ABP, mean ABP, lumbar SNA, and raw lumbar SNA
before and after KYN microinjection into the RVLM of LF, OR, and OP rats
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Figure 18. Summary data before and after KYN microinjection into the
RVLM of LF, OR, and OP rats
Summary data of (A) ABP and (B) lumbar SNA before and after RVLM
microinjection of KYN and peak changes in (C) ABP and (D) lumbar SNA after
bilateral microinjection of KYN into the RVLM of LF (ABP: n=8, SNA: n=7), OR
(ABP: n=10, SNA=7), and OP (ABP: n=9, SNA: n=9) rats. * P<0.05 OP vs LF or
OR rats, + P<0.05 vs baseline, # P<0.05 vs aCSF microinjection.
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Figure 19. Representative traces from LF, OR, and OP rats before and after
losartan microinjection into the RVLM
Representative examples of ABP, mean ABP, lumbar SNA, and raw lumbar SNA
before and after losartan microinjection into the RVLM of LF, OR, and OP rats
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Figure 20. Representative traces from LF, OR, and OP rats before and after
SHU 9119 microinjection into the RVLM
Representative examples of ABP, mean ABP, lumbar SNA, and raw lumbar SNA
before and after SHU 9119 microinjection into the RVLM of LF, OR, and OP rats
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Figure 21. Peak changes in ABP and lumbar SNA in LF, OR, and OP rats
Peak changes in ABP and lumbar SNA after bilateral microinjection of aCSF,
KYN, losartan, or SHU 9119 into the RVLM of LF (ABP: n=8-9, SNA: n=7), OR
(ABP: n=7, SNA: n=3-6), and OP (ABP: n=8-10, SNA: n=7-8) rats. # P<0.05 vs
aCSF microinjection.
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Figure 22. Peak change in ABP and lumbar SNA following unilateral Lglutamate microinjection into the RVLM of LF, OR, and OP rats
Peak changes in ABP and lumbar SNA after unilateral microinjection of Lglutamate (0.1 nmol, 60nL) into the RVLM of LF, OR, and OP rats. There was no
significant difference between changes in any of the 3 groups.
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Figure 23. Microinjection sites of KYN into the RVLM of LF, OR, and OP rats
Schematic drawings of RVLM injection sites of KYN (

LF,

OR, and

OP

rats). Microinjections of losartan, SHU 9119, and aCSF were similar in location
(data not shown). Sections represent -11.6 mm (top) and -11.9 mm (bottom) in
reference to bregma. IO indicates inferior olive; p, pyramidal tracts; NA, nucleus
ambiguous; ST, spinal trigeminal nucleus

Copyright © Megan E. Bardgett 2010
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Chapter V: General Discussion and Conclusions
Obesity is associated with many adverse health effects including essential
hypertension. This elevation in ABP is believed to stem from a central origin
leading to activation of the sympathetic nervous system. Hyperinsulinemia is
unequivocally linked with obesity and is known to activate the sympathetic
nervous system. Therefore, my dissertation sought to identify the neural circuits
that mediate insulin-induced sympathoexcitation and obesity-induced
hypertension as well as to investigate the potential role that insulin might play in
obesity hypertension.
These are the first studies to identify a specific brain region and receptor
system involved in the elevation of SNA and ABP during hyperinsulinemia and
obesity-induced hypertension. These studies present several important findings:
1) plasma insulin concentration is significantly increased in OP rats, 2) OP rats
have significantly elevated lumbar SNA and ABP compared to LF or OR rats, 3)
diet-induced obesity does not cause resistance to the sympathoexcitatory
response to hyperinsulinemia, 4) blockade of NMDA-specific glutamatergic
RVLM receptors reverses the increase in lumbar SNA associated with
hyperinsulinemia, 5) blockade of RVLM AT1 or melanocortin 3/4 receptors does
not affect the sympathoexcitatory response to insulin, 6) the RVLM expresses a
low concentration of insulin receptors, 7) microinjection of insulin into the RVLM
does not increase lumbar SNA, 8) blockade of RVLM glutamate receptors lowers
lumbar SNA and ABP in diet-induced obesity hypertension, and 9) blockade of
RVLM AT1 or melanocortin 3/4 receptors does not lower SNA or ABP in LF, OR,
or OP rats.
Acute hyperinsulinemic-euglycemic clamps activate the sympathetic
nervous system in both humans and rodents (Anderson et al. 1992, Morgan et al.
1993, Muntzel et al. 1994) though a physiologically relevant dose of insulin had
never been identified. By comparison of plasma insulin levels to diet-induced
obese and obese Zucker rats, we were able to identify a dose of insulin that
resulted in comparable levels to that in the varying obese rodent models. It was
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this dose of insulin that was subsequently used in all experiments and we did not
feel it necessary to use elevated doses as that would result in supraphysiologic
plasma insulin levels.
Whether insulin plays a role in activating the sympathetic nervous system
and elevating ABP in diet-induced obesity has been a point of contention for
many years. A major argument against a role for insulin in this process is that
obese humans and rodents become hyperinsulinemic and develop insulin
resistance. The efficiency with which skeletal muscle takes up glucose is
severely compromised with obesity as is the reduction in food intake normally
associated with centrally administered insulin. These findings lead to the belief
that insulin could not be responsible for the known increase in SNA in obesity.
Therefore, it was of critical importance to illustrate the capability of insulin to
increase SNA during diet-induced obesity even when peripheral tissues have
become insulin-resistant. The findings presented here illustrate that after
development of obesity and onset of peripheral insulin resistance, central circuits
are still responsive and produce an elevation in lumbar SNA in OP rats
equivalent to that in both LF and OR rats.
The model of diet-induced obesity utilized in these studies produces
characteristics similar to human obesity. OP rats show activation of the reninangiotensin system, hyperleptinemia, hyperinsulinemia, elevated sympathetic
outflow and elevated ABP (Boustany et al. 2004, Boustany et al. 2005, Levin et
al. 1983, Dobrain et al. 2000, Levin and Keesey 1998). OP rats show elevated
lumbar SNA and although renal SNA was not measured in these experiments,
renal denervation prevents the development of diet-induced obesity hypertension
(Kassab et al. 1995), indicating activation similar to that in obese humans (Vaz et
al. 1997). Therefore, this model presents with characteristics best suited to
examine that which occurs naturally in human obesity.
It is unknown whether obesity affects insulin‟s ability to access the central
nervous system. Little or no insulin is produced within the brain (Banks 2004)
and insulin crosses the blood-brain barrier in a transport specific method (Banks
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WA 1997). The blood brain barrier is a mostly impenetrable barrier separating
the brain from the substances circulating in the periphery. The capillary bed of
the blood brain barrier is not leaky and contains many tight junctions which
eliminate intercellular spaces. Blood borne substances are able to cross the
blood brain barrier in one of two ways: 1) lipid soluble molecules can diffuse
across the capillary membrane or 2) large or insoluble molecules utilize saturable
transport systems. Molecules such as insulin, glucose, and free fatty acids cross
through a transport mechanism. In the case of obesity, plasma insulin levels are
elevated but whether this is associated with an increase in cerebrospinal fluid
(CSF) insulin concentration is largely unknown. A multitude of studies have
examined the effects of obesity on CSF insulin concentration but the results are
varying. Measurement of CSF insulin in Zucker rats demonstrated that obese
Zucker rats have a significant increase in baseline CSF insulin compared to lean
controls (Stein et al. 1983, Stein et al. 1987), while insulin transport was not
affected in a model of diet-induced obesity (Israel et al. 1993). In agreement,
CSF insulin levels in obese humans are decreased following a 21 day diet (Owen
et al. 1974). In contrast, a study in dogs reported that insulin transport into the
CSF was decreased when dogs were placed on a high fat diet for seven weeks
(Kaiyala et al. 2000). A similar study showed that the ratio of plasma/CSF insulin
was negatively correlated with body mass index, though it is unclear what the
relationship was between raw CSF insulin values and body mass index (Kern et
al. 2006). In the present studies, if insulin transport was decreased in OP rats a
blunted sympathoexcitatory response to hyperinsulinemia would have been
expected. Instead; LF, OR, and OP rats showed similar sympathoexcitatory
responses to hyperinsulinemia, even a significantly greater increase in lumbar
SNA when expressed as microvolts, which indicates no difference in insulin
transport across the blood-brain barrier though future studies could involve direct
measurement of CSF insulin concentrations.
Having identified a potential role for insulin to act centrally to activate the
sympathetic nervous system it was important to examine the neural circuitry
involved in mediating this response. From these studies it can be ascertained
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that RVLM glutamatergic receptors are mediating both obesity-induced
hypertension as well as the sympathoexcitatory effect of hyperinsulinemia.
There are two varieties of glutamate receptors, ionotropic and metabotropic.
Ionotropic glutamate receptors are ligand-gated ion channels with rapid onset
and decay. The two types of ionotropic glutamate receptors, NMDA and AMPA,
are located on RVLM neurons. KYN which is a non-specific, competitive
glutamate receptor antagonist blocks both NMDA and AMPA receptors. AMPA
channels mediate fast synaptic transmission via Na + specific flow while NMDA
channels are non-specific cation channels mostly permitting flow of Na + and
Ca2+. NMDA channels allow for long-lasting increases in glutamate receptors
and their sensitivity and its ion channel only opens when glutamate is bound to
the receptor and the cell is already depolarized removing the Mg 2+ block
(Monaghan et al. 1989). NMDA-specific channels mediate the
sympathoexcitatory response to hyperinsulinemia while more studies are needed
in order to determine whether NMDA or AMPA receptors specifically mediate
obesity-induced hypertension.
Under normotensive conditions, blockade of RVLM ionotropic
glutamatergic receptors with KYN has no effect on either SNA or ABP.
Historically this was interpreted as glutamate playing no role in maintaining
resting SNA and ABP although recent studies have hypothesized an alternate
conclusion. Following inhibition of the caudal ventrolateral medulla, which sends
a tonic inhibitory signal to the RVLM, KYN microinjection into the RVLM causes a
profound decrease in ABP similar to that seen following ganglionic blockade (Ito
and Sved 1997). From these findings, it is believed that glutamate is
simultaneously activating both an excitatory and inhibitory pathway through the
RVLM. Given that, it is believed that under normotensive conditions KYN causes
an equivalent change in both excitatory and inhibitory inputs to the RVLM, though
it should be noted that a very similar study found opposing results in that RVLM
glutamate receptor blockade following CVLM inhibition did not lower ABP to
below baseline levels and the reason for the opposing results is not known
(Horiuchi et al. 2004). In the instances of hyperinsulinemia and diet-induced
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obesity, KYN causes a significant decrease in SNA and ABP most likely because
there is a shift from an equal balance between excitatory and inhibitory inputs to
one predominated by excitation.
Based on our findings, it would be predicted that activity of presympathetic RVLM excitatory neurons would be increased, which was shown to
be true in spontaneously hypertensive rats (Matsuura et al. 2002), or that a larger
population of said neurons are being activated. Future studies are needed to
measure in vivo RVLM neuronal activity during hyperinsulinemic-euglycemic
clamps and diet-induced obesity hypertension. This would also allow for
differentiation between increased neuronal activity versus recruitment of once
silent neurons. In addition, this would permit identification of the phenotypic
characteristics of RVLM neurons activated during these conditions. There are
two distinct populations of neurons comprising the RVLM: C1 and non-C1 cells.
C1 cells comprise more than 50% of spinally projecting RVLM neurons, contain
phenylethanolamine N-methyltransferase (PNMT), the rate limiting enzyme in
production of epinephrine, and have fast and slow conduction velocities.
Depletion of RVLM C-1 neurons produces either no change or a small, but
significant decrease in ABP and blunts many sympathoexcitatory reflexes
(Schreihofer et al. 2000, Madden and Sved 2003). While non-C1 cells do not
contain PNMT and have fast conduction velocities (Schreihofer and Guyenet
1997). It is possible that non-C1 neurons are involved in generating basal
sympathetic tone as depletion of C1 neurons does not cause a profound
decrease in resting ABP and SNA, but there is no method to target these
particular neurons.
Hyperinsulinemia increases baroreflex gain in both humans and rodents
(Pricher et al. 2007, Young et al. 2010). The neural circuitry through which
insulin acts to significantly alter baroreflex gain is not known. It is believed to be
within the hypothalamus as lateral ventricle infusion of insulin, but not 4 th
ventricle infusion, increases baroreflex gain. In this study we did not examine the
effect of hyperinsulinemic-euglycemic clamps on any sympathoexcitatory
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reflexes. Additional studies could examine the effect of intravenous
hyperinsulinemia on the arterial baroreflex, somatic pressor reflex, and
chemoreflex. It would be interesting to investigate whether the pathways
mediating insulin‟s possible effects on those sympathetic reflexes might overlap
with the pathways involved in the sympathoexcitation associated with
hyperinsulinemia.
Hyperinsulinemic-euglycemic clamps selectively activate lumbar SNA,
though others have shown a delayed increase in renal SNA (Rahmouni et al.
2004). Renal SNA is elevated in obese humans (Esler. 2006, Vaz et al. 1997)
and renal denervation prevents the development of diet-induced obesity
hypertension in dogs (Kassab et al. 1997). Though the particular studies
presented here did not investigate the contribution of renal SNA to diet-induced
obesity or the effects that receptor blockade might have on renal SNA, future
studies are needed to determine the role of renal SNA given that there is
abundant evidence that renal SNA plays a critical role in the development of
many forms of hypertension.
A major question that arises from the data presented here is the origin of
the glutamatergic projection to the RVLM during hyperinsulinemia and dietinduced obesity hypertension. There is a glutamatergic projection from the
hypothalamic paraventricular nucleus (Stocker et al. 2006) and previous
evidence illustrates a role for the hypothalamic paraventricular nucleus in
mediating insulin‟s sympathoexcitatory effect (Stocker et al. 2008). Very recent
studies provide evidence that the glutamatergic projection originates from the
hypothalamic paraventricular nucleus during hyperinsulinemia (Ward et al. In
Press) but it is still unknown during obesity-induced hypertension. Given that
nearly all neurons express ionotropic glutamate receptors, it is more useful to
examine expression of vesicular glutamate transporters (V-GLUT) which are
responsible for transporting glutamate into synaptic vesicles (Juge et al. 2006)
prior to release. There are three major forms of V-GLUT; V-GLUT 1, V-GLUT 2,
and V-GLUT 3 which are expressed in neurons though the function of V-GLUT 3
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has not been elucidated. There are many brain regions which project to the
RVLM including the caudal ventrolateral medulla (Afarwal and Calaresu 1991),
hypothalamic paraventricular nucleus (Shafton et al. 1998), pontine reticular
formation (Hayes K et al. 1994), nucleus of the solitary tract (Ross et al. 1985)
area postrema (Shapiro and Miselis 1985), central amygdaloid nucleus
(Takayama and Miura 1991), parabrachial nucleus (Krukoff et al. 1993), lateral
hypothalamic area (Allen and Cechietto 1992), and the raphe nucleus (Ross et
al. 1985), but not all are known to express V-GLUT transporters. V-GLUT 1 and
2 are expressed in the nucleus of the solitary tract (Lachamp et al. 2006),
hypothalamic paraventricular nucleus (Ziegler et al. 2002) and lateral
hypothalamic area (Ziegler et al. 2002) while V-GLUT 2 alone is expressed on
area postrema neurons (Stornetta et al. 2002). V-GLUT 3 is expressed on raphe
nucleus neurons (Yamakawa and Antle 2010). Those areas that express VGLUT and project to the RVLM require further study in regards to the increase in
glutamate receptor activation during diet-induced obesity hypertension.
Neither RVLM AT1 nor melanocortin 3/4 receptors mediate the
sympathoexcitatory response to insulin or diet-induced obesity hypertension.
There is abundant evidence that both systems mediate these responses but it is
clear that their involvement does not occur in the RVLM. Given that inhibition of
angiotensin converting enzyme with captopril blunts the sympathoexcitatory
effects of insulin (Muntzel et al.1994) while intracerebroventricular blockade of
AT1 receptors inhibits the pressor response to hyperinsulinemia (Nakata et al.
1998) it can be ascertained that the central RAS plays a critical role during
hyperinsulinemia. As well, because blockade of the RAS is used as an effective
therapy in hypertensive patients and is shown to lower SNA in obesehypertensive subjects (Grassi et al. 2003, BechirM et al. 2005) it is likely that the
RAS is activated upstream of the RVLM. In regards to the melanocortin system,
melanocortin-4 receptor knockout mice are resistant to the sympathoexcitatory
response of insulin but do not develop obesity-induced hypertension despite
elevated plasma insulin concentrations. As well, melanocortin 4 receptors are
found on ARC POMC neurons known to control food intake. Therefore, future
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studies are needed to ascertain where these systems are working in the central
nervous system. Similar studies to those performed here need to be completed
in brain areas such as the hypothalamic paraventricular nucleus and ARC, both
of which are implicated in the control of SNA and ABP and contain AT1 and
melanocortin receptors (Song et al. 1991, Kishi et al. 2003).
These studies do not provide an answer to the major question of where
insulin is sensed in the central nervous system to result in sympathoexcitation.
Here, we demonstrate that direction injection into the RVLM does not increase
lumbar SNA (Bardgett et al. 2010). The hypothalamic paraventricular nucleus
has direct projections to the RVLM but microinjection of insulin directly into the
hypothalamic paraventricular nucleus causes no change in lumbar SNA
(unpublished). Therefore, it is likely that the increase in insulin concentration is
sensed upstream of the hypothalamic paraventricular nucleus. A first step in
identifying a potential brain region that senses increased insulin would be to
examine the expression of c-fos immediately following ICV insulin administration.
C-fos is a proto-oncogene whose transcription is up-regulated following neuronal
activation. This would provide a preliminary indication of potential regions to
investigate further. As well, when insulin binds to its receptor, it results in autophosphorylation of tyrosine residues on the β-subunit and activation of PI3K.
Examining the changes in insulin receptor phosphorylation and PI3K activity
would also help in identifying the brain region responsible for sensing insulin.
Based on studies investigating insulin‟s effects on food intake, I would
hypothesize that insulin is sensed in the ARC. The ARC has a higher
concentration of insulin receptors than any other brain region (Hill et al. 1986,
Werther et al. 1987) and lesions of the ARC prevent the anorexic effects of
insulin (Schwartz et al. 2000). In addition, PI3K activity is increased in ARC
neurons following intracerebroventricular insulin in a time frame that corresponds
with the increase in lumbar SNA during IV infusion of insulin (Niswender et al.,
2003). Taken together, future studies need to be performed in order to
determine a role for the ARC. Inhibition of the ARC, with the GABA agonist
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muscimol, is needed to establish a role for the ARC in the sympathoexcitatory
response, though this would not determine if the ARC is responsible for sensing
insulin. Direct microinjection of insulin into the ARC would be the first step in
determining its role. Rats could also be pretreated with a lentivirus for the insulin
receptor in order to knock down receptor function specifically in the ARC. In
combination these studies would ascertain the role of the ARC during insulininduced sympathoexcitation. Figure 24 illustrates a hypothesized pathway
through which insulin increases lumbar SNA and ABP. The ARC has a direct
projection to the hypothalamic paraventricular nucleus (Cone 2005) which has a
monosynaptic glutamatergic projection to the RVLM.
It is known that insulin acts in the hypothalamus to decrease food intake
and hypothesized that it acts in the same or neighboring location to activate the
sympathetic nervous system. Insulin activates POMC neurons, increasing αMSH which binds melanocortin receptors resulting in a decrease in food intake
while simultaneously inhibiting NPY/AgRP neurons causing a decrease in
NPY/AgRP mRNA and protein release (Figure 1). Though this pathway has
been implicitly studied it is still unclear how insulin binding results in such
changes in protein expression and release. Direct insulin application to
hypothalamic neurons in vitro causes hyperpolarization through opening of ATPsensitive K+ channels (Spanswick et al. 2000). How hyperpolarization of
hypothalamic neurons which occurs within seconds translates into activation of
the sympathetic nervous system and a decrease in food intake over a
significantly longer period of time is unclear. In addition, although the immediate
effects of insulin are hyperpolarizing, there is an increase in PI 3K and PIP3
expression after central insulin administration, the hallmark insulin signaling
pathway, whose time frame of activation correlates with the increase in lumbar
SNA associated with hyperinsulinemia. To further complicate the story, leptin,
which acts through a PI3K dependent pathway similar to insulin (Hill et al. 2008)
to decrease food intake, causes POMC ARC neurons to depolarize (Williams et
al. 2010) and NPY/AgRP neurons to hyperpolarize (Spanswick et al. 1997).
Further studies are clearly needed in order to elucidate the significance of insulin89

induced hyperpolarization and how it leads to increased POMC expression and
activation of the PI3K pathway through which insulin works. This would include
recording from POMC ARC neurons in vivo during intracerebroventricular
administration of insulin to determine if the in vitro effects of insulin hold true in
an in vivo preparation.
Chronic hyperinsulinemic-euglycemic clamps elevate ABP in rodents
through an increase in total peripheral resistance (Brands et al. 1991) and
although acute clamps increase muscle SNA in humans, ABP is not elevated.
Similar results were found in dogs although SNA was not measured. In acute
settings, insulin has vasodilatory effects in the periphery and it is possible that
this vasodilation counteracts the increase in muscle SNA resulting in no net
change in ABP. For experimental reasons, it is not possible to determine
whether hyperinsulinemia would elevate ABP in a chronic setting in humans.
Obesity is associated with many factors that could potentially contribute to
activation of the sympathetic nervous system and elevation in ABP. Obese
models in animals tend to be associated with the same physiological alterations.
Therefore, it is nearly impossible to ascertain which alterations are leading to
activation in SNA and elevation in ABP. From these studies highlighting insulin‟s
continued ability to stimulate the sympathetic nervous system even after
development of obesity leaves open the possibility that insulin could be one
factor involved. Obesity also results in selective resistance to leptin, with an
ability to still activate renal SNA but not lumbar or brown adipose tissue SNA
(Rahmouni et al. 2005). From these studies, it is most likely a combination of
factors that contribute to the sympathoexcitation and elevated ABP associated
with obesity.
Summary
The studies within this dissertation have clearly demonstrated that
physiological levels of circulating insulin activate the sympathetic nervous system
under normal and diet-induced obese conditions. This is important because it
highlights a potential role for insulin in mediating the sympathoexcitatory effect of
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obesity as well as the elevated ABP. We were also able to begin to identify the
neural pathway through which insulin and obesity work to elevate SNA and ABP.
From this we discovered that both hyperinsulinemia and diet-induced obesity
activate a glutamatergic pathway through the RVLM. In the case of
hyperinsulinemia, it was specific to NMDA-glutamatergic receptors. In contrast,
we showed that neither AT1 nor melanocortin 3/4 RVLM receptors are involved
in mediating the cardiovascular response to hyperinsulinemia or diet-induced
obesity.
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Figure 24. Hypothesized pathway through which insulin acts to elevate
lumbar SNA and ABP
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